UV FILTER COMPOSITIONS COMPRISING CLOSED-CELL METAL OXIDE PARTICLES

Abstract
The present invention relates to a method for increasing sun protection factor (SPF) of a UV filter composition, use of closed-cell metal oxide particles for increasing SPF of a UV filter composition and UV filter compositions comprising the closed-cell metal oxide particles.
Description
FIELD OF THE INVENTION

The present invention relates to a method for increasing sun protection factor (SPF) of a UV filter composition, use of closed-cell metal oxide particles for increasing SPF of a UV filter composition and UV filter compositions comprising the closed-cell metal oxide particles.


BACKGROUND OF THE INVENTION

UV filter compositions are used to prevent adverse effects of solar radiations on human skin. A wide variety of UV absorbers are available, and a UV filter composition often comprises one or more UV absorber/s to achieve a high UV protection, i.e., a high sun protection factor (SPF).


However, challenges still exist for obtaining a UV filter composition having a high SPF. Several UV filters are characterized by a low solubility in the commonly used formulation media, and hence incorporation of a high amount of such a low-solubility UV filter in a UV filter composition becomes difficult. Further, the highest amount of a UV filter that can be incorporated in a UV filter composition is controlled by government regulations. Therefore, there exists a need for methods for increasing the SPF of a UV filter composition.


An agent used for increasing SPF of a UV filter composition may lead to undesired effects such as scattering of solar radiations, thereby resulting in an unpleasant appearance such as whitening of face. Therefore, it is desired that the method for increasing the SPF of a UV filter composition maintains its transparency and does not lead to undesired effects such as whitening effect.


Accordingly, it is an object of the invention to provide a method for increasing SPF of a UV filter composition. Further, it is an object of the invention to provide a UV filter composition that is not associated with adverse appearance problems such as whitening effect.


SUMMARY OF THE INVENTION

It has been surprisingly found that the sun protection factor (SPF) of a UV filter composition can be increased by adding closed-cell metal oxide particles to the UV filter composition.


Accordingly, an aspect of the presently claimed invention is directed to a method for increasing the sun protection factor of a UV filter composition, the method comprising adding closed-cell metal oxide particles to the UV filter composition. The closed-cell metal oxide particles comprise a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a void volume, wherein the outer surface of the closed-cell metal oxide particles is defined by the array of closed-cells. The metal oxide matrix comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof.


Another aspect of the presently claimed invention is directed to use of closed-cell metal oxide particles for increasing the sun protection factor of a UV filter composition. The closed-cell metal oxide particles comprise a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a void volume, wherein the outer surface of the closed-cell metal oxide particles is defined by the array of closed-cells. The metal oxide matrix comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof.


Yet another aspect of the presently claimed invention is directed to a UV filter composition comprising closed-cell metal oxide particles in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition. The closed-cell metal oxide particles comprise a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a void volume, wherein the outer surface of the closed-cell metal oxide particles is defined by the array of closed-cells. The metal oxide matrix comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof.





BRIEF DESCRIPTION OF DRAWINGS


FIG. 1 is a graph showing the absorbance of the UV filter composition 1 (placebo), composition 2 (3 wt. % closed-cell metal oxide particles according to example 2) and composition 4 (comparative) in the range from 290 to 450 nm.



FIG. 2 is a graph showing the absorbance of the UV filter composition 1 (placebo), composition 2 (3 wt. % closed-cell metal oxide particles according to example 2) and composition 3 (commercial UV protection boosts) in the range from 290 to 450 nm.



FIG. 3 depicts a chart related to the lightness value L* of the UV filter compositions 1 (placebo), 2 (3 wt. % closed-cell metal oxide particles according to example 2) and composition 3 (commercial UV protection boosts).





f


DETAILED DESCRIPTION

Before the present compositions and formulations of the presently claimed invention are described, it is to be understood that this invention is not limited to the particular compositions and formulations described, since such compositions and formulation may, of course, vary. It is also to be understood that the terminology used herein is not intended to be limiting, since the scope of the presently claimed invention will be limited only by the appended claims.


If hereinafter a group is defined to comprise at least a certain number of embodiments, this is meant to also encompass a group which preferably consists of these embodiments only. Furthermore, the terms ‘first’, ‘second’, ‘third’ or ‘a’, ‘b’, ‘c’, etc. and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments of the presently claimed invention described herein are capable of operation in other sequences than described or illustrated herein. In case the terms ‘first’, ‘second’, ‘third’ or ‘(A)’, ‘(B)’ and ‘(C)’ or ‘(a)’, ‘(b)’, ‘(c)’, ‘(d)’, ‘i’, ‘il’ etc. relate to steps of a method or use or assay there is no time or time interval coherence between the steps, that is, the steps may be carried out simultaneously or there may be time intervals of seconds, minutes, hours, days, weeks, months or even years between such steps, unless otherwise indicated in the application as set forth herein above or below.


Furthermore, the ranges defined throughout the specification include the end values as well i.e., a range of 1 to 10 implies that both 1 and 10 are included in the range. For the avoidance of doubt, applicant shall be entitled to any equivalents according to applicable law.


In the following passages, different aspects of the presently claimed invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.


Reference throughout this specification to ‘one embodiment’ or ‘an embodiment’ means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the presently claimed invention. Thus, appearances of the phrases ‘in one embodiment’ or ‘in an embodiment’ in various places throughout this specification are not necessarily all referring to the same embodiment but may refer to so.


Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to a person skilled in the art from this disclosure, in one or more embodiments. Furthermore, while some embodiments described herein include some, but not other features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the presently claimed invention, and form different embodiments, as would be understood by those in the art. For example, in the appended claims, any of the claimed embodiments can be used in any combination.


It has been found that closed-cell metal oxide particles can be used to increase the SPF of a UV filter composition. The presently claimed invention provides a method for increasing SPF of a UV filter compositions and also provides UV filter compositions having a high SPF. Further, it is observed that the resultant UV filter composition does not show adverse appearance effects such as the whitening effect, which is usually associated with the addition of agents that scatter radiations.


The closed cell metal oxide particles are structural colorants that interact with UV and visible radiations via light interference effects. Structural colorants are materials containing nano-sized structured surfaces small enough to interfere with visible light and produce color. Bulk samples of closed-cell metal oxide particles exhibit saturated color with reduced unwanted light scattering when porosity and/or microsphere diameter and/or pore diameter are within a certain range. As a result, the presence of closed-cell metal oxide particles in a UV filter composition leads to a decrease in the amount of the radiations travelling through the UV filter composition layer. Thus, an overall decrease in transmittance of the dye or the UV absorber is achieved without increasing its concentration.


Accordingly, an aspect of the presently claimed invention is directed to a method for increasing the sun protection factor of a UV filter composition, the method comprising adding closed-cell metal oxide particles to the UV filter composition, wherein the closed-cell metal oxide particles comprise a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a void volume, wherein the outer surface of the closed-cell metal oxide particles is defined by the array of closed-cells. The metal oxide matrix comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof.


Another aspect of the presently claimed invention is directed to use of closed-cell metal oxide particles for increasing the sun protection factor of a UV filter composition, wherein the closed-cell metal oxide particles comprise a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a void volume, wherein the outer surface of the closed-cell metal oxide particles is defined by the array of closed-cells. The metal oxide matrix comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof.


In a preferred embodiment, the void volume is media inaccessible.


In the context of the present invention, the SPF factor (sun protection factor, SPF) serves to evaluate light protection preparations (UV filter compositions) on humans (in vivo). It indi-cates how much longer a person with a UV filter agent can be exposed to the sun without suffering sunburn than would be possible with the particular individual's self-protection time. The SPF is determined in vitro by measuring the diffuse transmission in the spectral range between 290 and 400 nm.


In the context of the present invention, the term “monodisperse” in reference to spheres, microspheres or nanospheres means particles having generally uniform shapes and generally uniform diameters. A present monodisperse population of spheres, microspheres or nanospheres may have 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the particles by number having diameters within +7%, +6%, +5%, +4%, +3%, +2% or +1% of the average diameter of the population.


In the context of the present invention, the terms ‘particles’, ‘microspheres’, ‘microparticles’, ‘nanospheres’, ‘nanoparticles’, ‘droplets’ etc. also refer to, for example, a plurality thereof, a collection thereof, a population thereof, a sample thereof, or a bulk sample thereof.


In the context of the present invention, the term ‘bulk sample’ refers to a population of particles. For example, a bulk sample of particles is simply a bulk population of particles, for example, ≥0.1 mg, ≥0.2 mg, ≥0.3 mg, ≥0.4 mg, ≥0.5 mg, ≥0.7 mg, ≥1.0 mg, ≥2.5 mg, ≥5.0 mg, ≥10.0 mg, or ≥25.0 mg. A bulk sample of particles may be substantially free of other components.


In the context of the present invention, the phrase “exhibits color observable by the human eye” means color will be observed by an average person. This may be for any bulk sample distributed over any surface area, for example, a bulk sample distributed over a surface area of, for example, from any of 1 cm2, 2 cm2, 3 cm2, 4 cm2, 5 cm2, or 6 cm2 to any of 7 cm2, 8 cm2, 9 cm2, 10 cm2, 11 cm2, 12 cm2, 13 cm2, 14 cm2, or 15 cm2. It may also mean observable by a CIE 1931 2° standard observer and/or by a CIE 1964 10° standard observer. The background for color observation may be any background, for example, a white background, black background, or a dark background anywhere between white and black.


In the context of the present invention, the terms ‘micro’ or ‘micro-scaled’, for example, when referring to particles, mean from 1 micrometer (μm) to less than 1000 μm. The term ‘nano’ or ‘nano-scaled’, for example, when referring to particles, mean from 1 nanometer (nm) to less than 1000 nm.


In the context of the present invention, the term “media-inaccessible” with reference to a volume means that the volume is shielded from infiltration by large molecules (e.g., molecules, such as polymers and oligomers, having a molecular weight greater than 5000 g/mol). The volume may be accessible to solvents, such as water, toluene, hexane, and ethanol.


In the context of the present invention, the terms “microspheres”, “nanospheres”, “droplets”, etc., referred to herein may mean for example a plurality thereof, a collection thereof, a population thereof, a sample thereof or a bulk sample thereof.


In the context of the present invention, the term “micro” or “micro-scaled” means from about 0.5 μm to about 999 μm. The term “nano” or “nano-scaled” means from about 1 nm to about 999 nm.


In the context of the present invention, the terms “spheres” and “particles” may be interchangeable.


Unless otherwise indicated, all parts and percentages mentioned herein are by weight. Weight percent (wt. %), if not otherwise indicated, is based on an entire composition free of any vol-atiles, that is, based on dry solids content.


In a preferred embodiment, the amount of the closed-cell metal oxide particles is in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition.


In a preferred embodiment, the amount of the closed-cell metal oxide particles is in the range of 0.5 to 10.0 wt. % based on total weight of the UV filter composition.


In a preferred embodiment, the array of closed-cells is an ordered array.


In a preferred embodiment, the array of closed-cells is a disordered array.


The terms “ordered array” and “disordered array” of the closed-cells refer to the structure of the closed-cells defined by the metal oxides matrix. In case of an “ordered array”, the closed-cells have a structure of a repeating pattern in the matrix. According to a preferred embodiment, an ordered array results in an angle dependent colour. In case of an “disordered array”, the closed-cells have a random structure with no specific pattern in the matrix. According to a preferred embodiment, a disordered array results in an angle independent colour. The terms “ordered array of closed-cells” and “ordered voids” are meant to be understood interchangeably. The terms “disordered array of closed-cells” and “disordered voids” are meant to be understood interchangeably.


In a preferred embodiment, the closed-cell metal oxide particles have an average diameter in the range of 0.5 μm to 100.0 μm; more preferably 1.0 μm to 75.0 μm; even more preferably 2.0 μm to 50.0 μm; and most preferably 3.0 μm to 25.0 μm.


In a preferred embodiment, the closed-cell metal oxide particles comprise mainly the metal oxide, that is, they may consist essentially of or consist of metal oxide.


In a preferred embodiment, the amount of metal oxide in the closed-cell metal oxide particles is in the range of 60.0 to 100.0 wt. %; more preferably 65.0 to 99.9 wt. %; even more preferably 70.0 to 99.9 wt. %; and most preferably 75.0 to 99.0 wt. %, based on total weight of the closed-cell metal oxide particles.


In a preferred embodiment, the closed-cell metal oxide particles have an average pore diameter in the range of 3 nm to 500 nm.


In a preferred embodiment, the closed-cell metal oxide particles have an average pore diameter in the range of 3 nm to 400 nm.


In a preferred embodiment, the closed-cell metal oxide particles have an average pore diameter in the range of 3 nm to 300 nm; more preferably 10 nm to 300 nm; even more preferably 25 nm to 250 nm; and most preferably 50 nm to 200 nm.


In a preferred embodiment, the closed-cell metal oxide particles have an average porosity in the range of 0.10 to 0.90.


In a preferred embodiment, the closed-cell metal oxide particles have an average porosity in the range of 0.10 to 0.80, more preferably 0.20 to 0.75; even more preferably 0.30 to 0.70; and most preferably 0.40 to 0.70.


In a preferred embodiment, the metal oxide matrix comprises silica.


In a preferred embodiment, the metal oxide matrix comprises alumina.


In a preferred embodiment, the metal oxide matrix comprises titania.


In a preferred embodiment, the metal oxide matrix comprises silica and alumina.


In a preferred embodiment, the metal oxide matrix comprises silica and titania.


In a preferred embodiment, the metal oxide matrix comprises silica and zinc oxide.


Metal oxide particles are used for the preparation of the metal oxide matrix.


In a preferred embodiment, the metal oxide particles fuse with each other during the preparation, and result in a continuous metal oxide matrix.


In a preferred embodiment, a combination of two or more different types of metal oxide particles is used for the preparation of the closed-cell metal oxide particles. The combination of metal oxide particles may contain two or more populations having different compositions and/or morphologies.


In a preferred embodiment, the metal oxide particles comprise two or more populations having different particle sizes.


In a preferred embodiment, the metal oxide particles comprise particles such that each particle is made of two or more different metal oxides.


In a more preferred embodiment, the metal oxide particles comprise particles such that each particle is made of silica and titania.


In a preferred embodiment, the closed-cells are monodisperse.


In a preferred embodiment, the closed-cells have a bimodal distribution of monodisperse closed-cells.


In a preferred embodiment, the closed-cells are polydisperse.


In a preferred embodiment, the closed-cell metal oxide particles are prepared using a polymeric sacrificial template.


According to one embodiment of the invention, the closed-cell metal oxide particles have an additional sealing layer. The sealing layer may span over several or all closed-cells of a closed-cell metal oxide particle. In a particularly preferred embodiment, the sealing layer comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof. It is most preferred that the sealing layer comprises silica.


According to another embodiment of the invention, the closed-cell metal oxide particles are free of a sealing layer.


In a preferred embodiment, the closed-cell metal oxide particles are prepared by a method comprising the following steps.

    • generating liquid droplets from a particle dispersion comprising first particles comprising a polymer material and second particles comprising a metal oxide material;
    • drying the liquid droplets to provide dried particles comprising an array of the first particles, wherein each of the first particles is coated by a layer of the second particles; and
    • calcining or sintering the dried particles, wherein the calcining or sintering densifies the metal oxide material and removes the polymer material to produce the closed-cell metal oxide particles each comprising a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a void volume, and wherein outer surfaces of the closed-cell metal oxide particles are defined by their respective arrays of closed-cells.


In a preferred embodiment, the first particles comprise net positive charged surfaces, and the second particles comprise net negative charged surfaces.


In a preferred embodiment, the first particles comprise net negative charged surfaces, and the second particles comprise net positive charged surfaces.


In a preferred embodiment, the surface charges drive the formation of the layer of the second particles on the first particles.


In a preferred embodiment, the polymer material comprises a polymer selected from poly(meth)acrylic acid, poly(meth)acrylates, polystyrenes, polyacrylamides, polyethylene, polypropylene, polylactic acid, polyacrylonitrile, a co-polymer of methyl methacrylate and [2-(methacryloyloxy)ethyl] trimethylammonium chloride, derivatives thereof, salts thereof, copolymers thereof, or mixtures thereof.


In a preferred embodiment, the first particles have an average diameter from 50 nm to 500 nm.


In a preferred embodiment, the metal oxide material comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and combinations thereof.


In a preferred embodiment, the second particles have an average diameter from 1 nm to 120 nm.


In a preferred embodiment, the generating the liquid droplets is performed using a microfluidic process.


In a preferred embodiment, the generating and drying the liquid droplets is performed using a spray-drying process.


In a preferred embodiment, the generating the liquid droplets is performed using a vibrating nozzle.


In a preferred embodiment, the drying the droplets comprises evaporation, microwave irradi-ation, oven drying, drying under vacuum, drying in the presence of a desiccant, or a combination thereof.


In a preferred embodiment, the particle dispersion is an aqueous particle dispersion.


In a preferred embodiment, a weight ratio of the first particles to the second particles is selected from 1/10 to 10/1.


In a preferred embodiment, a weight ratio of the first particles to the second particles is selected from 2/3, 1/1, 3/2, or 3/1.


In a preferred embodiment, a particle size ratio of the second particles to the first particles is selected from 1/50 to 1/5.


In a preferred embodiment, the closed-cell metal oxide particles are prepared by a method comprising:

    • generating liquid droplets from a particle dispersion comprising polymer in a sol-gel matrix of a metal oxide material, the polymer particles comprising a polymer material;
    • drying the liquid droplets to provide dried particles comprising an array of the polymer particles, wherein each of the polymer particles is coated by the sol-gel matrix; and
    • calcining or sintering the dried particles to obtain the closed-cell metal oxide particles, wherein the calcining or sintering removes the polymer material and densifies the metal oxide material to produce the closed-cell metal oxide particles each comprising a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a media-inaccessible void volume, and wherein outer surfaces of the closed-cell metal oxide particles are defined by their respective arrays of closed-cells.


In a preferred embodiment, the polymer particles comprise net positive charged surfaces, and the sol-gel matrix of the metal oxide material comprises a net negative charge.


In a preferred embodiment, the polymer particles comprise net negative charged surfaces, and the sol-gel matrix of the metal oxide material comprises a net positive charge.


Advantageously, depending on the compositions of the metal oxide particles, their relative sizes, and shapes, a bulk sample of the closed-cell metal oxide particles may exhibit a color observable by the human eye, may appear white, or may exhibit properties in the range of UV spectrum.


A bulk sample of the closed-cell metal oxide particles described herein may exhibit angle-dependent color or angle-independent color. “Angle-dependent” color means that observed color has dependence on the angle of incident light on a sample or on the angle between the observer and the sample. “Angle-independent” color means that observed color has substantially no dependence on the angle of incident light on a sample or on the angle between the observer and the sample.


In a preferred embodiment, the angle dependent color is achieved with an ordered array of the closed-cells.


In a preferred embodiment, the angle independent color is achieved with a disordered array of the closed-cells.


In a preferred embodiment, the angle dependent color is achieved when the closed-cells are monodisperse.


In a preferred embodiment, angle independent color is achieved when the closed-cells are polydisperse.


In a preferred embodiment, angle independent color is achieved when the closed-cells exhibit a bimodal distribution of monodisperse polymer particles.


In a preferred embodiment, angle independent color is achieved independently of the poly-dispersity and shapes of the matrix particles.


Any of the embodiments exhibiting angle dependent or angle independent color may be modified to exhibit whiteness or effects in the ultraviolet spectrum.


In a preferred embodiment, the closed-cell metal oxide particles

    • a. have an average diameter in the range of 0.5 μm to 100.0 μm;
    • b. have an average porosity in the range of 0.10 to 0.90;
    • c. have an average pore diameter in the range of 3 nm to 500 nm; and
    • d. comprise monodisperse closed-cells.


In a preferred embodiment, the closed-cell metal oxide particles

    • a. have an average diameter in the range of 0.5 μm to 100.0 μm;
    • b. have an average porosity in the range of 0.10 to 0.90;
    • c. have an average pore diameter in the range of 3 nm to 500 nm; and
    • d. comprise closed-cells having a bimodal distribution of monodisperse closed-cell metal oxide particles.


In a preferred embodiment, the closed-cell metal oxide particles

    • a. have an average diameter in the range of 0.5 μm to 100.0 μm;
    • b. have an average porosity in the range of 0.10 to 0.90;
    • C. have an average pore diameter in the range of 3 nm to 500 nm; and
    • d. comprise polydisperse closed-cells.


In a preferred embodiment, the closed-cell metal oxide particles further comprise a light absorber.


In a preferred embodiment, the light absorber is present in the range of 0.1 to about 40.0 wt. %, more preferably 0.5 to 25.0 wt. %; and most preferably 1.0 to 10.0 wt. %.


In a preferred embodiment, the light absorber comprises at least one ionic species.


In a preferred embodiment, the closed-cell metal oxide particles exhibit color in the visible spectrum at a wavelength in the range of 380 nm to 800 nm.


In a preferred embodiment, the closed-cell metal oxide particles exhibit effect in a wavelength range in the ultraviolet spectrum selected from the group consisting of 100 nm to 400 nm.


In a preferred embodiment, the closed-cell metal oxide particles exhibit a wavelength range in the ultraviolet and visible spectrum selected from the group consisting of 200 nm to 500 nm.


In a preferred embodiment, the UV filter composition comprises an UV absorber selected from the group consisting of

    • (d1) p-aminobenzoic acid derivatives;
    • (d2) salicylic acid derivatives;
    • (d3) benzophenone derivatives;
    • (d4) dibenzoylmethane derivatives;
    • (d5) diphenyl acrylates;
    • (d6) 3-imidazol-4-yl-acrylic acid and it's esters;
    • (d7) benzofuran derivatives;
    • (d8) polymeric UV absorbers;
    • (d9) cinnamic acid derivatives;
    • (d10) camphor derivatives;
    • (d11) hydroxyphenyltriazine derivatives;
    • (d12) benzotriazole derivatives;
    • (d13) trianilino-s-triazine derivatives;
    • (d14) 2-phenylbenzimidazole-5-sulfonic acid, and salts thereof;
    • (d15) methyl o-aminobenzoates;
    • (d16) homosalates;
    • (d17) tris-biphenyltriazine derivatives;
    • (d18) TiO2, ZnO and mica;
    • (d19) benzylidenemalonates;
    • (d20) merocyanine derivatives;
    • (d21) phenylene bis-diphenyltriazines;
    • (d22) imidazoline derivatives;
    • (d23) diarylbutadiene derivatives;
    • (d24) amino hydroxybenzoyl hexyl benzoate derivatives;
    • (d25) bis-(diethylamino hydroxybenzoyl benzoyl)-piperazine derivatives, and mixtures thereof.


Examples of p-aminobenzoic acid derivatives (d1) which can be employed according to the presently claimed invention, are 4-aminobenzoic acid (PABA); ethyldihydroxypropyl-PABA of the formula




embedded image


PEG-25-PABA of the formula




embedded image


wherein m, n and x have the same meaning, and each denote an integer from 1 to 25; octyl-dimethyl PABA of the formula




embedded image


or glycyl aminobenzoate of the formula




embedded image


Example for salicylic acid derivatives (d2) which can be employed according to the presently claimed invention, are

    • homomenthyl salicylate of the formula
    • (SAD-01)




embedded image


triethanolamine salicylate of the formula




embedded image


amyl p-dimethylaminobenzoate of the formula




embedded image


octyl salicylate of the formula




embedded image


or 4-isopropylbenzyl salicylate of the formula




embedded image


Example for benzophenone derivatives (d3) which can be employed according to the presently claimed invention, are:

    • benzophenone-3-(2-hydroxy-4-methoxybenzophenone); benzophenone-4-(2-hydroxy-4-methoxybenzophenone-5-sulfonic acid); benzophenone-8-(2,2′-dihydroxy-4-methoxybenzophenone); or amino-substituted hydroxybenzophenones of the formula




embedded image


wherein

    • R1 and R2 denote hydrogen, C1-C20-alkyl, C2-C10-alkenyl, C3-C10-cycloalkyl, C3-C10-cycloalkenyl, wherein the substituents R1 and R2 together with the nitrogen atom to which they are bonded can form a 5- or 6-membered ring;
    • R3 and R4 independently of each other denote C1-C20-alkyl; C2-C10-alkenyl; C3-C10-cycloalkyl; C3-C10-cycloalkenyl; C1-C22-alkoxy; C1-C20-alkoxycarbonyl; C1-C12-alkylamino; C1-C12-dialkylamino; optionally substituted aryl; hetaryl; substituents conferring solubility in water selected from the group consisting of a nitrile group, and carboxylate, sulfonate or ammonium radicals; X denotes hydrogen; COOR5; or CONR6R7;
    • R5, R6, R7 independently of each other denote hydrogen; C1-C20-alkyl; C2-C10-alkenyl; C3-C10-cycloalkyl; C3-C10-cycloalkenyl; (Y—O)o—Z; or aryl;
    • Z denotes —CH2—CH3; —CH2—CH2—CH3; —CH2—CH2—CH2—CH3; or —CH(CH3)—CH3;
    • m denotes 0 to 3;
    • n denotes 0 to 4; and
    • o denotes 1 to 20.


In a more preferred embodiment, the UV absorber is 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid.


Benzophenone derivatives (d3) also include dimeric benzophenone derivatives corresponding to the formula




embedded image


wherein

    • R1 and R2 independently of each other denote C1-C20-alkyl; C2-C20-alkenyl; C3-C10-cycloalkyl; C3-C10-cycloalkenyl; or R1 and R2 together with the nitrogen atom to which they are bonded form a 5- or 6-membered heterocyclic ring;
    • R3 denotes alkylene, cycloalkylene, alkenylene or phenylene optionally substituted by a carbonyl or carboxyl group; a biradical of the formula




embedded image


or

    • R3 together with A forms a bivalent radical of the formula




embedded image


wherein

    • n2 denotes an integer from 1 to 3;
    • A denotes —O—; or —N(R5)—; and
    • R5 denotes hydrogen; C1-C5-alkyl; or hydroxy-C1-C5-alkyl;
    • can also be employed according to the invention.


In a more preferred embodiment, dimeric benzophenone derivatives of the formula




embedded image


are employed as UV absorbers (d3).


Examples of dibenzoylmethane derivatives (d4) which can be employed according to the presently claimed invention are butylmethoxydibenzoylmethane-[1-(4-tert-butylphenyl)-3-(4-methoxyphenyl) propane-1,3-dione].


Examples of diphenylacrylate derivatives (d5) which can be employed according to the presently claimed invention are octocrylene-(2-ethylhexyl 2-cyano-3,3′-diphenylacrylate) or etocrylene (ethyl 2-cyano-3,3′-diphenylacrylate).


Examples of benzofuran derivatives (d7) which can be employed according to the presently claimed invention are 3-(benzofuranyl) 2-cyanoacrylate, 2-(2-benzofuranyl)-5-tert-butylben-zoxazole or 2-(p-aminophenyl)benzofuran and in particular the compounds of the formula




embedded image


Examples of polymeric UV absorbers (d8) which can be employed according to the presently claimed invention and contain one or more organosilicon radicals are benzylidenemalonate derivatives, in particular the compound of the formula




embedded image


wherein Ra denotes hydrogen or methoxy and r denotes approximately 7; the compound of the formula




embedded image


or polysilicone-15 corresponding to the formula




text missing or illegible when filed


Examples of cinnamic acid esters (d2) which can be employed according to the presently claimed invention are octyl methoxycinnamate (4-methoxycinnamic acid 2-ethylhexyl ester), diethanolamine methoxycinnamate (diethanolamine salt of 4-methoxycinnamic acid), isoamyl p-methoxycinnamate (4-ethoxycinnamic acid 2-isoamyl ester), 2,5-diisopropyl methycinnamate or a cinnamic acid amido derivative.


Examples of camphor derivatives (d10) which can be employed according to the presently claimed invention are 4-methylbenzylidenecamphor-[3-(4′-methyl)benzylidenebornan-2-one], 3-benzylidenecamphor-(3-benzylidenebornan-2-one), polyacrylamidomethylbenzyli-denecamphor {N-[2 (and 4)-2-oxyborn-3-ylidenemethyl)benzyl] acrylamide polymer), trimoni-umbenzylidenecamphor sulfate-[3-(4′-trimethylammonium)-benzylidenebornan-2-one me-thylsulfate], terephthalydenedicamphorsulfonic acid {3,3′-(1,4-phenylenedimethine)-bis-(7,7-dimethyl-2-oxobicyclo-[2.2.1]heptane-1-methanesulfonic acid} or salts thereof, or ben-zylidenecamphorsulfonic acid [3-(4′-sulfo)benzylidenebornan-2-one] or salts thereof.


Examples of hydroxyphenyltriazine derivatives (du) which can be employed according to the invention are, in particular, bis-resorcinyltriazines of the formula




embedded image


wherein

    • R1 and R2 independently of each other denote hydrogen; C1-C18-alkyl; C2-C18-alkenyl; a radical of the formula —CH2—CH(—OH)—CH2—O—T1; a radical of the formula




embedded image


or a radical of the formula (HPT-01h)




embedded image




    • R3, R4 and R5 independently of each other denote hydroxyl; C1-C5-alkoxy which is unsubstituted or substituted by one or more OH groups; amino; mono- or di-C1-C5-alkylamino; M; a radical of the formula







embedded image




    • R10, R11 and R12 independently of each other denote C1-C14-alkyl which is unsubstituted or substituted by one or more OH groups;

    • R13 denotes hydrogen; M; C1-C5-alkyl; or a radical of the formula-(CH2) m3-O-T1;

    • R6 denotes the direct bond; a straight-chain or branched C1-C4-alkylene radical; or a radical of the formula —Cm4H2m4, or —Cm4H2m4—O—;

    • R7, R. and R9 independently of each other denote C1-C18-alkyl; C1-C18-alkoxy or a radical of the formula







embedded image




    • R14 denotes C1-C5-alkyl;

    • M denotes a metal cation;

    • T1 denotes hydrogen; or (C1-C8)-alkyl;

    • m1, m2 and m3 independently of each other denote 1 to 3;

    • m4 denotes 2 to 14; and

    • P1 denotes 0 or a number from 1 to 5.





In a preferred embodiment, the compound class (du) are:

    • 2-(4′-methoxyphenyl)-4,6-bis(2′-hydroxy-4′-n-octyloxyphenyl)-1,3,5-triazine;
    • 2,4-bis {[4-(3-(2-propyloxy)-2-hydroxypropyloxy)-2-hydroxy] phenyl}-6-(4-methoxy-phenyl)-1,3,5-triazine;
    • 2,4-bis {[4-(2-ethylhexyloxy)-2-hydroxy] phenyl}-6-[4-(2-methoxyethylcarboxyl)phenylamino]-1,3,5-triazine;
    • 2,4-bis {[4-(tris(trimethylsiloxysilylpropyloxy)-2-hydroxy] phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine;
    • 2,4-bis {[4-(2″methylpropenyloxy)-2-hydroxy] phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine;
    • 2,4-bis {[4-(1′,1′,1′,3′,5′,5′,5′-heptamethyltrisilyl-2″-methylpropyloxy)-2-hydroxy] phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine;
    • 2,4-bis {[4-(3-(2-propyloxy)-2-hydroxypropyloxy)-2-hydroxy] phenyl}-6-[4-ethylcar-boxyl)phenylamino]-1,3,5-triazine;
    • 2,4-bis {[4-(2-ethylhexyloxy)-2-hydroxy] phenyl}-6-(1-methylpyrrol-2-yl)-1,3,5-triazine; or
    • 2,2′-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl] bis [5-[(2-ethylhexyl)oxy]-(bis-ethylhexyloxyphenol methoxyphenyl triazine) corresponding to the formula




embedded image


Examples of benzotriazole derivatives (d12) which can be employed according to the presently claimed invention correspond to the formula




embedded image


wherein

    • R1 denotes hydrogen; C1-C12-alkyl; C1-C12-alkoxy; C1-C12-alkoxycarbonyl; C5-C10-cycloalkyl or —SO3M;
    • R3 denotes hydrogen; C1-C18-alkyl; C1-C12-alkoxy; or halogen; and
    • n denotes 1 or 2;
    • if n=1
    • R2 denotes C1-C20-alkyl; C5-C10-cyclo-C1-C5-alkyl; C1-C12-alkoxy-C1-C5-alkyl; C5-C10-cyclo-alkoxy-C1-C5-alkyl; C6-C10-aryl; C6-C10-aryl-C1-C5-alkyl;
    • if n=2
    • R2 denotes the direct bond; or —(CH2)p—; and
    • p is an integer from 1 to 3.


In a preferred embodiment, compounds of the formula (BT-01), wherein

    • R1 denotes C1-C12-alkyl; or —SO3M;
    • R3 denotes hydrogen; halogen, preferably CI;
    • n denotes 1;
    • R2 C1-C12-alkyl; and
    • p denotes 1 to 3;
    • are possible.


In a more preferred embodiment, the benzotriazole derivatives (d12) are compounds of the formula




embedded image


In a more preferred embodiment, UV filters of the formula BT-01 are compounds wherein

    • R1 denotes hydrogen;
    • R3 denotes C1-C18-alkyl;
    • n=2; and
    • R2 denotes —CH2—.


In a more preferred embodiment, the benzotriazole derivatives (d12) are compounds of the formula




embedded image


Examples of trianilino-s-triazine derivatives (d13) which can be employed according to the presently claimed invention correspond to the formula




embedded image


wherein

    • R1, R2 and R3 independently of each other denote optionally substituted C1-C20-alkyl, aryl or hetaryl;
    • x denotes O; or NR4; and
    • R4 denotes hydrogen; or optionally substituted C1-C20-alkyl, aryl or hetaryl.


In a preferred embodiment, trianilino-s-triazine derivatives (d13) compound is ethylhexyl triazone corresponding to the formula




embedded image


or Diethylhexyl butamido triazone corresponding to the formula




embedded image


or Ethylhexyl bis-Isopentylbenzoxazolylphenyl melamine corresponding to the formula




embedded image


Examples of 2-phenylbenzimidazole-5-sulfonic acid, and salts thereof (d14) which can be employed according to the invention is Disodium 2,2′-(1,4-phenylene)bis(6-sulfo-1/-1,3-ben-zimidazole-4-sulfonate (Bisdisulizole disodium).


Examples of tris-biphenyl-triazine derivatives (d17) which can be employed according to the invention correspond to the formula




embedded image


wherein


A denotes a radical of the formula




embedded image


or




embedded image




    • R1 and R5 independently of each other denote hydrogen; C1-C18-alkyl; or C6-C12-aryl;

    • R2, R3 and R4 independently of each other denote hydrogen; or a radical of the formula







embedded image


wherein in formula (TBT-01a) at least one of the radicals R2, R3 and R4 denotes a radical of the formula (TBT-01c);

    • R6, R7, R8, R9 and R10 independently of each other denote hydrogen; hydroxyl; halogen; C1-C18-alkyl; C1-C18-alkoxy; C6-C12-aryl; biphenylyl; C6-C12-aryloxy; C1-C18-alkylthio; carboxyl; —COOM;
    • C1-C18-alkylcarboxyl; aminocarbonyl; or mono- or di-C1-C18-alkylamino; C1-C10-acylamino; —COOH;
    • M denotes an alkali metal ion;
    • x denotes 1 or 2; and
    • y denotes an integer from 2 to 10.


In a preferred embodiment, the UV filters (d17) which can be employed according to the presently claimed invention correspond to the compounds of the formula




embedded image


Examples of benzylidenemalonates (d19) which can be employed according to the invention correspond to the formula




embedded image


wherein

    • R1 denotes methyl; ethyl; propyl; or n-butyl
    • if R1 denotes methyl,
    • R denotes tert butyl;




embedded image


a radical of the formula




embedded image


or a radical of the formula




embedded image


wherein

    • R2 and R3 independently of each other hydrogen; or methyl;
    • R4 methyl; ethyl; or n-propyl;
    • R5 and R6 independently of each other hydrogen; or C1-C3-alkyl;
    • if R1 denotes ethyl; propyl; or n-butyl,
    • R denotes isopropyl.


In a preferred embodiment, benzylidenemalonates (d19) which can be employed according to the presently claimed invention are listed in the following table:












Examples of benzylidenemalonates which can be used according to the presently claimed


invention




embedded image















R1
R





(MBM-02)
methyl


embedded image







(MBM-03)
methyl


embedded image







(MBM-04)
methyl


embedded image







(MBM-05)
methyl


embedded image







(MBM-06)
methyl


embedded image







(MBM-07)
methyl


embedded image







(MBM-08)
methyl


embedded image







(MBM-09)
methyl


embedded image







(MBM-10)
methyl


embedded image







(MBM-11)
ethyl


embedded image







(MBM-12)
propyl


embedded image







(MBM-13)
n-butyl


embedded image







(MBM-14)
methyl


embedded image







(MBM-15)
methyl


embedded image











An example of the phenylene-bis-diphenyltriazines (d21) which can be employed according to the presently claimed invention is 5,6,5,6-tetraphenyl-3,3′-(1,4-phenylene)-bis [1,2,4]triazine corresponds to the formula




embedded image


An example of the imidazoline derivatives (d22) which can be employed according to the presently claimed invention, is Ethylhexyldimethoxybenzylidenedioxoimidazoline propionate.


An example of the diarylbutadiene derivatives (d23) which can be employed according to the presently claimed invention, is 1,1-dicarboxy-(2,2′-dimethylpropyl)-4,4-diphenylbutadiene.


Examples of amino hydroxybenzoyl hexyl benzoate derivatives (d24) which can be employed according to the invention is 2-(4-Diethylamino-2-hydroxybenzoyl)benzoicacid hexylester corresponds to the formula




embedded image


Examples of bis-(diethylamino hydroxybenzoyl benzoyl)-piperazine derivatives (d25) which can be employed according to the invention corresponds to the formula




embedded image


Each of the abovementioned UV filters (d1)-(d25) can be used according to the presently claimed invention as a mixture. For example, mixtures of two, three, four, five or six of the filter groups (d1)-(d25) can be used according to the presently claimed invention. Mixtures of two, three, four, five or six UV filters from one or more representatives of substance classes (d1)-(d25) can also be used according to the invention.


In a preferred embodiment, the UV filters (d) are representatives of the following compound classes:

    • (d1) p-aminobenzoic acid derivatives;
    • (d2) salicylic acid derivatives;
    • (d3) benzophenone derivatives;
    • (d4) dibenzoylmethane derivatives;
    • (d5) diphenyl acrylates;
    • (d6) 3-imidazol-4-yl-acrylic acid and its esters;
    • (d7) benzofuran derivatives;
    • (d8) cinnamic acid derivatives;
    • (d10) camphor derivatives;
    • (d11) hydroxyphenyltriazine derivatives;
    • (d12) benzotriazole derivatives;
    • (d13) trianilino-s-triazine derivatives;
    • (d15). methyl o-aminobenzoates;
    • (d16) homosalates;
    • (d19) benzylidenemalonates; and
    • (d20) merocyanine derivatives.


In a more preferred embodiment, the following oil-soluble UV filters are used according to the invention:

    • (dSOL-1) Benzophenone-3 (BP3);
    • (dSOL-2) Benzophenone-4 (BP4);
    • (dSOL-3) 3-Benzylidene Camphor (3BC);
    • (dSOL-4) Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine (BEMT);
    • (dSOL-5) Butyl Methoxydibenzoylmethane (BMBM);
    • (dSOL-6) Diethylhexyl Butamido Triazone (DBT);
    • (dSOL-7) Drometrizole Trisiloxane (DTS);
    • (dSOL-8) Ethylhexyl Triazone (EHT);
    • (dSOL-9) Ethylhexyl Methoxycinnamate;
    • (dSOL-10) Benzylidenemalonate (BM);
    • (dSOL-11) Diethylamino Hydroxy Benzoyl Hexyl Benzoate (DHHB);
    • (dSOL-12) Octocrylene;
    • (dSOL-13) Polysilicone-15;
    • (dSOL-14) Homosalate;
    • (dSOL-15) Ethylhexyl salicylate; and
    • (dSOL-16) Merocyanine.


In a more preferred embodiment, the following particulate UV filters are used according to the invention:

    • Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (nano) (MBBT);
    • Tris-Biphenyl Triazine (nano) (TBPT);
    • Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (nano) (BDBP); and
    • Phenylene Bis-Diphenyltriazine (PBDT).


In a most preferred embodiment, the UV filter is at least one selected from the group consisting of

    • (d9a) Ethylhexyl Methoxycinnamate,
    • (d11a) Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine,
    • (d13a) Ethylhexyl Triazone,
    • (d3a) Diethylamino Hydroxy Benzoyl Hexyl Benzoate,


Merocyanine





    • Methylene Bis-Benzotriazolyl Tetramethylbutylphenol (nano) (MBBT);

    • Tris-Biphenyl Triazine (nano) (TBPT); and

    • Bis-(Diethylaminohydroxybenzoyl Benzoyl) Piperazine (nano) (BDBP).





In a particularly preferred embodiment, the UV filter is a mixture of UV filters selected from the group consisting of (d9a), (d11a), (d13a) and (d3a).


In a preferred embodiment, the method or use protects the skin against ultraviolet radiation and high energy visible light.


In a preferred embodiment, the protects the skin against ultraviolet radiation having a wavelength in the range from 280 and 400 nm, and high energy visible light in the range of wavelength from 380 to 480 nm.


In a preferred embodiment, the method or use protects the skin against high energy visible light of wavelength in the range from 380 to 480 nm.


It has been observed that the increase in the absorbance due to the presence of closed-cell metal oxide particles is stronger in the UV spectral range compared to the visible range.


In a preferred embodiment, the method further minimizes or masks the whitening effect of the UV filter composition and maintains its transparency.


In a preferred embodiment, the use further minimizes or masks the whitening effect of the UV filter composition and maintains its transparency.


UV Filter Compositions Comprising Closed-Cell Metal Oxide Particles

Another aspect of the presently claimed invention is directed to a UV filter composition comprising closed-cell metal oxide particles in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition. The closed-cell metal oxide particles comprise a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a void volume, wherein the outer surface of the closed-cell metal oxide particles is defined by the array of closed-cells. The metal oxide matrix comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof.


In a preferred embodiment, the void volume is media inaccessible.


In a preferred embodiment, the UV filter composition comprises

    • (i) water; and
    • (ii) closed-cell metal oxide particles in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition.


In a preferred embodiment, the UV filter composition comprises

    • (i) water; and
    • (ii) closed-cell metal oxide particles in the range of 0.5 to 10.0 wt. % based on total weight of the UV filter composition.


In a preferred embodiment, the UV filter composition comprises

    • a. water;
    • b. oil; and
    • c. the closed-cell metal oxide particles in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition.


In a preferred embodiment, the oil is present in the form of a discontinuous phase in the range of 5.0 to 50.0 wt. %, based on total weight of the UV filter composition.


In a preferred embodiment, the water is present in the form of a discontinuous phase in the range of 5.0 to 50.0 wt. %, based on total weight of the UV filter composition.


In a preferred embodiment, the UV filter composition comprises

    • (i) oil; and
    • (ii) closed-cell metal oxide particles in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition.


In a preferred embodiment, the UV filter composition comprises

    • (i) oil; and
    • (ii) closed-cell metal oxide particles in the range of 0.5 to 10.0 wt. % based on total weight of the UV filter composition.


In a preferred embodiment, the amount of the metal oxide in the closed-cell metal oxide particles is in the range of 60.0 to 100.0 wt. %, based on total weight of the closed-cell metal oxide particles.


In a preferred embodiment, the closed-cell metal oxide particles have an average diameter in the range of 0.5 μm to 100.0 μm.


In a preferred embodiment, the closed-cell metal oxide particles have an average porosity in the range of 0.10 to 0.90.


In a preferred embodiment, the closed-cell metal oxide particles have an average porosity in the range of 0.10 to 0.80.


In a preferred embodiment, the closed-cell metal oxide particles have an average pore diameter in the range of 3 nm to 500 nm.


In a preferred embodiment, the closed-cell metal oxide particles further comprise a light (UV-visible) absorber.


In a preferred embodiment, the light (UV-visible) absorber is present in the range of 0.1 wt. % to 40.0 wt. %.


In a preferred embodiment, the UV filter composition further comprises an UV absorber selected from the group consisting of

    • (d1) p-aminobenzoic acid derivatives;
    • (d2) salicylic acid derivatives;
    • (d3) benzophenone derivatives;
    • (d4) dibenzoylmethane derivatives;
    • (d5) diphenyl acrylates;
    • (d6) 3-imidazol-4-yl-acrylic acid and its esters;
    • (d7) benzofuran derivatives;
    • (d8) polymeric UV absorbers;
    • (d9) cinnamic acid derivatives;
    • (d10) camphor derivatives;
    • (d11) hydroxyphenyltriazine derivatives;
    • (d12) benzotriazole derivatives;
    • (d13) trianilino-s-triazine derivatives;
    • (d14) 2-phenylbenzimidazole-5-sulfonic acid and salts thereof;
    • (d15) methyl o-aminobenzoates;
    • (d16) homosalates;
    • (d17) tris-biphenyltriazine derivatives;
    • (d18) TiO2, ZnO and mica;
    • (d19) benzylidenemalonates;
    • (d20) merocyanine derivatives;
    • (d21) phenylene bis diphenyltriazines;
    • (d22) imidazoline derivatives;
    • (d23) diarylbutadiene derivatives;
    • (d24) amino hydroxybenzoyl hexyl benzoate derivatives;
    • (d25) bis-(diethylamino hydroxybenzoyl benzoyl)-piperazine derivatives; and mixtures thereof.


Representative examples of the UV absorbers are described hereinabove.


In a preferred embodiment, the UV filter composition is sunscreen composition.


In a preferred embodiment, the UV filter composition is day care composition.


In a preferred embodiment, the UV filter composition is at least one selected from the group consisting of creams, gels, lotions, alcoholic solutions, aqueous/alcoholic solutions, emulsions, wax/fat compositions, stick preparations, powders and ointments.


Presentation Forms

The final UV filter composition listed may exist in a wide variety of presentation forms, for example:

    • in the form of liquid preparations as a W/O, O/W, O/W/O, W/O/W or PIT emulsion and all kinds of microemulsions,
    • in the form of a gel,
    • in the form of an oil, a cream, milk or lotion,
    • in the form of a powder, a lacquer, a tablet or make-up,
    • in the form of a stick,
    • in the form of a spray (spray with propellant gas or pump-action spray) or an aerosol,
    • in the form of a foam, or
    • in the form of a paste.


Of special importance as UV filter compositions for the skin are light-protective preparations, such as sun milks, lotions, creams, oils, sunblocks or tropicals, pretanning preparations or after-sun preparations, also skin-tanning preparations, for example self-tanning creams. Of particular interest are sun protection creams, sun protection lotions, sun protection milk and sun protection preparations in the form of a spray.


In addition the UV filter compositions may contain further adjuvants as described below.


1) Oil Phase

In the context of the present invention, possible oily substances are, for example, Guerbet alcohols based on fatty alcohols having 6 to 18, preferably 8 to 10 carbon atoms (e.g. Eutanol® G), esters of linear C6-C22-fatty acids with linear or branched C6-C22-fatty alcohols and esters of branched C6-C13-carboxylic acids with linear or branched C6-C22-fatty alcohols, such as e.g. myristyl myristate, myristyl palmitate, myristyl stearate, myristyl isostearate, myristyl oleate, myristyl behenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl isostearate, cetyl oleate, cetyl behenate, cetyl erucate, stearyl myristate, stearyl palmitate, stearyl stearate, stearyl isostearate, stearyl oleate, stearyl behenate, stearyl erucate, isostearyl myristate, isostearyl palmitate, isostearyl stearate, isostearyl isostearate, isostearyl oleate, isostearyl behenate, oleyl myristate, oleyl palmitate, oleyl stearate, oleyl isostearate, oleyl oleate, oleyl behenate, oleyl erucate, behenyl myristate, behenyl palmitate, behenyl stearate, behenyl isostearate, behenyl oleate, behenyl behenate, behenyl erucate, erucyl myristate, erucyl palmitate, erucyl stearate, erucyl isostearate, erucyl oleate, erucyl behenate and erucyl erucate. In addition, esters of linear C6-C22-fatty acids with branched alcohols, in particular 2-ethylhexanol, esters of C3-C38-alkylhydroxycarboxylic acids with linear or branched C6-C22-fatty alcohols, in particular diethylhexyl malate, esters of linear and/or branched fatty acids with polyhydric alcohols (such as e.g. propylene glycol, dimer diol or trimer triol) and/or Guerbet alcohols, triglycerides based on C6-C10-fatty acids, liquid mono/di/triglyceride mixtures based on C6-C18-fatty acids, esters of C6-C22-fatty alcohols and/or Guerbet alcohols with aromatic carboxylic acids, in particular benzoic acid, esters of C2-C12-dicarboxylic acids with linear or branched alcohols having 1 to 22 carbon atoms or polyols having 2 to 10 carbon atoms and 2 to 6 hydroxyl groups, plant oils, branched primary alcohols, substituted cyclo-hexanes, linear and branched C6-C22-fatty alcohol carbonates, such as e.g. Dicaprylyl Carbonate (Cetiol® OE), Guerbet carbonates based on fatty alcohols having 6 to 18 preferably 8 to 10 C atoms, esters of benzoic acid with linear and/or branched C6-C22-alcohols (e.g. Fin-solv® TN), linear or branched, symmetric or unsymmetric dialkyl ethers having 6 to 22 carbon atoms per alkyl group, such as e.g. dicaprylyl ether (Cetiol® OE), ring-opening products of epoxidized fatty acid esters with polyols (Hydagen® HSP, Sovermol® 750, Sovermol®1102), silicone oils (cyclomethicone, silicon methicone types and others) and/or aliphatic or naph-thenic hydrocarbons, such as e.g. mineral oil, vaseline, petrolatum, squalane, squalene, iso-hexadecane or dialkylcyclohexanes are suitable in consideration.


In certain embodiments, the oily substances are medium-polarity oils, in particular esters of C2-C12-dicarboxylic acids with linear or branched alcohols having 1 to 22 carbon atoms and/or linear and branched C6-C22-fatty alcohol carbonates, adipic acid esters of linear or branched alcohols having 1 to 22 carbon atoms, very particularly of linear alcohols having 1 to 6 carbon atoms, are particularly suitable here.


Linear and branched fatty alcohol carbonates, in particular dicaprylyl carbonate, are particularly preferably used as oily substance.


In a more preferred embodiment, dibutyl adipate is used as oily substance.


In a even more preferred embodiment, the oil phase is selected from C12-15 alkyl benzoate, dibutyl adipate, dicaprylyl carbonate, propylheptyl caprylate, caprylic/capric triglyceride, dicaprylyl ether, butylene glycol dicaprylate/dicaprate, coco-caprylate, octyldodecanol, di-propylheptyl carbonate, caprylyl-caprylate/caprate, cocoglycerides, ethylhexyl stearate, iso-hexadecane, isopropyl palmitate, and isopropyl myristate.


In another embodiment, the amount of oil phase is in the range of 20 to 35 wt. %, based on total weight of the UV filter composition.


2) Surfactant

In certain embodiments, the UV filter composition further comprises at least one surfactant in the range of 1.0 to 20.0 wt. %, based on total weight of the UV filter composition.


In certain embodiments, the surfactant is selected from an anionic surfactant, a nonionic surfactant, and a polymeric surfactant.


The anionic surfactants are characterized by one or more anionic group which confers solubility in water, such as e.g., a carboxylate, sulfate, sulfonate or phosphate group, and a lipo-philic radical. In addition, the molecule can contain polyglycol ether, ester, ether and hydroxyl groups. Anionic surfactants which are tolerated by skin are known to the person skilled in the art in large numbers from relevant handbooks and are commercially obtainable.


Representative examples of the preferred anionic surfactants are, in each case in the form of their salts, ether-carboxylic acids, acylsarcosides having 8 to 24 C-atoms in the acyl group, acyltaurides having 8 to 24 C-atoms in the acyl group, acylisethionates having 8 to 24 C-atoms in the acyl group, sulfosuccinic acid mono- and dialkyl esters having 8 to 24 C-atoms in the alkyl group and sulfosuccinic acid monoalkyl polyoxyethyl esters having 8 to 24 C-atoms in the alkyl group and 1 to 6 oxyethyl groups, linear alkanesulfonates having 8 to 24 C-atoms, linear alpha-olefinsulfonates having 8 to 24 C-atoms, alpha-sulfo-fatty acid methyl esters of fatty acids having 8 to 30 C-atoms, alkyl sulfates, alkyl polyglycol ether sulfates, esters of tartaric acid and citric acid, alkyl and/or alkenyl ether phosphates, sulfated fatty acid alkylene glycol esters, monoglyceride sulfates and monoglyceride ether sulfates as well as condensation products of C8-C30-fatty alcohols with protein hydrolysates and/or amino acids and derivatives thereof, so-called protein fatty acid condensates, e.g. Lamepon®, Gluadin®, Hosta-pon® KCG or Amisoft®.


The salts of these surfactants are preferably selected from the sodium, potassium and ammonium and the mono-, di- and trialkanalammonium salts having 2 to 4 C-atoms in the alkanol group.


Particularly suitable anionic surfactants are liquid at room temperature, preferably from 18 to 25° C. A desirable feature in particular of these anionic surfactants is that they have a low water content of at most 10 wt. %, preferably 0.1 to 5 wt. %, based on the total weight of the anionic surfactant.


In a most preferred embodiment, the anionic surfactants are alk(en)yl polyglycol ether citrates and in particular mixtures of mono-, di- and triesters of citric acid and alkoxylated alcohols which correspond to the formula (I):




embedded image


wherein

    • R1, R2 and R3 independently of each other denote hydrogen or the radical of the formula (II)





R4(OCH2CHR5)n


wherein

    • R4 represents a linear or branched alkyl and/or alkenyl radical having 6 to 22 carbon atoms,
    • R5 represents hydrogen or a methyl radical, and
    • n represents a number from 1 to 20, with the condition that at least one of the radicals
    • R1, R2 or R3 is other than hydrogen.


Typical examples of the alcohol part of the esters are addition products of on average 1 to 20 mol, preferably 5 to 10 mol of ethylene oxide and/or propylene oxide on caproyl alcohol, capryl alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmitolelyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, arachyl alcohol, gadoleyl alcohol, behenyl alcohol, erucyl alcohol and brassidyl alcohol and technical grade mixtures thereof.


Such alk (en) yl polyglycol ether citrates are advantageous for the agents according to the invention since they are liquid anionic surfactants having a low water content of maximum 5 wt. %, based on the anionic surfactant.


The anionic surfactants are preferably present in amounts in the range of 7 to 17 wt. %, based on total weight of the UV filter composition.


The agents according to the invention furthermore comprise at least (c) 0.5 to 25 wt. % of a further co-surfactant which differs from anionic surfactants.


Suitable co-surfactants are, in principle, zwitterionic, ampholytic, cationic and/or nonionic surfactants.


Those surface active compounds which carry at least one quaternary ammonium group and at least one —COO(−) or —SO3(−) group in the molecule are called zwitterionic surfactants. Particularly suitable zwitterionic surfactants are the so-called betaines, such as the N-alkyl-N,N-dimethylammonium glycinates, for example coco-alkyldimethylammonium glycinate, N-acyl-aminopropyl-N,N-dimethylammonium glycinates, for example coco-acylamimopropyldime-thylammonium glycinate, and 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazoline having in each case 8 to 18 C-atoms in the alkyl or acyl group, and coco-acylaminoethylhydroxyethyl-carboxymethyl glycinate. The fatty acid amide derivative known under the INCI name Cocam-idopropyl Betaine is a preferred zwitterionic surfactant. Tego® Betain 810 (INCI: Capryl/Capramidopropyl Betaine) and a surfactant mixture of Rewopol® SBCS 50K (INCI: Disodium PEG-5 Laurylcitrate Sulfosuccinate, Sodium Laureth Sulfate) and Tego® Betain 810 (Capryl/Capramidopropyl Betaine), in particular in the weight ratio of 1:4 to 4:1, very particularly preferably in the weight ratio of from 1:4 to 1:1, are particularly preferred according to the invention.


Ampholytic surfactants are understood as meaning those surface-active compounds which contain, apart from a C8-C18-alkyl or acyl group, at least one free amino group and at least one —COOH or —SO3H group in the molecule and are capable of formation of inner salts. Examples of suitable ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-al-kylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylgly-cines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids having in each case 8 to 18 C atoms in the alkyl group. Preferred ampholytic surfactants are N-coco-alkylaminopropionate, coco-acylaminoethylaminopropionate and C12-18-acylsar-cosine.


Quaternary ammonium compounds in particular can be used as cationic surfactants. Surfactants from this substance class have a particularly high affinity for the skin and can improve the degree of sensory smoothness. These include, inter alia, ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammo-nium chlorides and trialkylmethylammonium chlorides, e.g., cetyltrimethylammonium chlo-ride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, lauryldime-thylammonium chloride, lauryldimethylbenzylammonium chloride and tricetylmethylammo-nium chloride. The very readily biodegradable quaternary ester compounds, such as, for example, the dialkylammonium methosulfates and methylhydroxyalkyldialkoyloxyalkylammo-nium methosulfates marketed under the trade name Stepantex® and the corresponding products of the Dehyquart& series, can furthermore be employed as cationic surfactants. The term “esterquats” is in general understood as meaning quaternized fatty acid triethanolamine ester salts. They impart to the compositions particularly soft feel. These are known substances which are prepared by the relevant methods of organic chemistry. Further cationic surfactants which can be used according to the invention are the quaternized protein hydrolysates.


Nonionic surfactants are particularly preferably present as co-surfactants, for example

    • addition products of from 2 to 50 mol of ethylene oxide and/or 0 to 20 mol of propylene oxide on linear fatty alcohols having 8 to 40 C atoms, on fatty acids having 12 to 40 C atoms and on alkylphenols having 8 to 15 C atoms in the alkyl group;
    • C12/18-fatty acid mono- and diesters of addition products of from 1 to 50 mol of ethylene oxide on glycerol; glycerol mono- and diesters and sorbitan mono- and diesters of saturated and unsaturated fatty acids having 6 to 22 carbon atoms and ethylene oxide addition products thereof,
    • alkyl mono- and oligoglycoside having 8 to 22 carbon atoms in the alkyl radical and ethoxylated analogues thereof; addition products of from 7 to 60 mol of ethylene oxide on castor oil and/or hydrogenated castor oil;
    • polyol and/or polyglycerol esters, such as e.g., polyglycerol diisostearate or polyglycerol dimerate or polyglycerol 12-hydroxystearate;
    • addition products of from 2 to 15 mol of ethylene oxide on castor oil and/or hydrogenated castor oil;
    • partial esters based on linear, branched, unsaturated or saturated C6-C22-fatty acids, ricinoleic acid and 12-hydroxystearic acid with, pentaerythritol, dipentaerythritol, sugar alcohols (e.g., sorbitol), alkyl glucosides (e.g., methyl glucoside, butyl glucoside, lauryl glucoside) and polyglucosides (e.g., cellulose), or mixed esters, such as e.g., glyceryl stearate citrate and glyceryl stearate lactate;
    • wool wax alcohols;
    • polysiloxane/polyalkyl polyether copolymers and corresponding derivatives;
    • mixed esters of pentaerythritol, fatty acids, citric acid and fatty alcohol and/or mixed esters of fatty acids having 6 to 22 carbon atoms, methylglucose and polyols, preferably glycerol or polyglycerol; and
    • polyalkylene glycols.


The addition products of ethylene oxide and/or of propylene oxide on fatty alcohols, fatty acids, alkylphenols, glycerol mono- and diesters and sorbitan mono- and diesters of fatty acids or on castor oil are known, commercially obtainable products. These are homologue mixtures, the average degree of alkoxylation of which corresponds to the ratio of the substance amounts of ethylene oxide and/or propylene oxide and substrate with which the addition reaction is carried out. They are W/O or O/W emulsifiers, depending on the degree of ethoxylation. For the preparations according to the invention, the reaction products with 1-100 mol of ethylene oxide are particularly suitable.


Advantageous compounds from the group of nonionic surfactants are partial esters of polyols, in particular of C3-C6-polyols, such as, for example, glyceryl monoesters, partial esters of pentaerythritol or sugar esters, e.g. sucrose distearate, sorbitan monoisostearate, sorbitan ses-quiisostearate, sorbitan diisostearate, sorbitan triisostearate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, sorbitan trioleate, sorbitan monoerucate, sorbitan sesquieru-cate, sorbitan dierucate, sorbitan trierucate, sorbitan monoricinoleate, sorbitan sesquiricino-leate, sorbitan diricinoleate, sorbitan triricinoleate, sorbitan monohydroxystearate, sorbitan sesquihydroxystearate, sorbitan dihydroxystearate, sorbitan trihydroxystearate, sorbitan monotartrate, sorbitan sesquitartrate, sorbitan ditartrate, sorbitan tritartrate, sorbitan monocitrate, sorbitan sesquicitrate, sorbitan dicitrate, sorbitan tricitrate, sorbitan monoma-leate, sorbitan sesquimaleate, sorbitan dimaleate, sorbitan trimaleate and technical grade mixtures thereof. Addition products of from 1 to 30, preferably 5 to 10 mol of ethylene oxide on the sorbitan esters mentioned are also suitable nonionic surfactants.


Nonionic surfactants from the group of alkyl oligoglycosides are particularly skin-friendly and may therefore preferably be suitable in the context of the invention. C8-C22-alkyl mono- and oligoglycosides, their preparation and their use are known. Their preparation is carried out in particular by reaction of glucose or oligosaccharides with primary alcohols having 8 to 22 C atoms, preferably 12 to 22, and particularly preferably 12 to 18 C atoms. With respect to the glycoside radical, both monoglycosides in which a cyclic sugar residue is bonded glycosidically to the fatty alcohol and oligomeric glycosides having a degree of oligomerization of up to preferably 8 are suitable. The degree of oligomerization here is a statistical mean based on a conventional distribution of homologues for such technical grade products Products which are available under the name Plantacare& contain a glucosidically bonded C8-C16-alkyl group on an oligoglucoside radical, the average degree of oligomerization of which is 1 to 2. The acylglucamides derived from glucamine are also suitable as nonionic surfactants.


Nonionic surfactants, preferably polyol and/or polyglycerol esters, are very particularly preferably present as co-surfactants in the agents according to the invention as component (c), and/or alkyl oligoglycosides.


The polyol component of these surfactants can be derived from substances which have at least two, preferably 3 to 12 and in particular 3 to 8 hydroxyl groups and 2 to 12 carbon atoms.


Typical examples are:

    • glycerol and polyglycerol;
    • alkylene glycols, such as, for example, ethylene glycol, diethylene glycol, propylene gly-col;
    • methylol compounds, such as, in particular, trimethylolethane, trimethylolpropane, tri-methylolbutane, pentaerythritol and dipentaerythritol;
    • alkyl oligoglucosides having 1 to 22, preferably 1 to 8 and in particular 1 to 4 carbons in the alkyl radical, such as, for example, methyl and butyl glucoside;
    • sugar alcohols having 5 to 12 carbon atoms, such as, for example, sorbitol or mannitol;
    • sugars having 5 to 12 carbon atoms, such as, for example, glucose or sucrose;
    • amino-sugars, such as, for example, glucamine.


Reaction products based on polyglycerol are of particular importance because of their excel-lent use properties.


The acid component of these surfactants can be derived from straight-chain, branched, saturated and/or unsaturated carboxylic acids, optionally with functional groups, such as hydroxyl groups. The acid component is particularly preferably fatty acids having 12 to 22 carbon atoms, which optionally carry a hydroxyl group, and in particular hydroxystearic acid.


In a preferred embodiment of the invention the diester of polyhydroxystearic acid, polyglyceryl 2-dipolyhydroxystearate, which is marketed, for example, by BASF Personal Care and Nutri-tion GmbH under the name Dehymuls® PGPH is used as a glyceryl ester.


In a preferred embodiment of the invention Eumulgin® SG, Eumulgin® Prisma, Emulgade® sucro and Emulgade® Sucro Plus are used as surfactants.


In the agents according to the invention the further co-surfactants are conventionally present in an amount in the range of 0.5 to 25 wt. %; more preferably in the range of 3.0 to 18 wt. %; and particularly preferably in the range of 7 to 18 wt. %.


3) Additives

In certain embodiments, the UV filter composition further comprises additives selected from thickener, active ingredients, preservatives, and perfumes.


Thickeners

Suitable thickeners are anionic, zwitterionic, amphoteric and nonionic copolymers, such as, for example, vinyl acetate/crotonic acid copolymers, vinylpyrrolidone/vinyl acrylate copolymers, vinyl acetate/butyl maleate/isobornyl acrylate copolymers, methyl vinyl ether/maleic anhydride copolymers and esters thereof, acrylamidopropyltrimethylammonium chlo-ride/acrylate copolymers, octylacrylamide/methyl methacrylate/tert-butylaminoethyl meth-acrylate/2-hydroxypropyl methacrylate polymers, vinylpyrrolidone/vinyl acetate copolymers, vinylpyrrolidone/dimethylaminoethyl methacrylate/vinylcaprolactam terpolymers and optionally polysaccharides, in particular xanthan gum, guar and guar derivatives, agar-agar, alginates and tyloses, cellulose and cellulose derivatives, such as carboxymethylcellulose, carboxymethylcellulose and hydroxycellulose and moreover silicones.


Preferably, thickeners selected from the group of polyacrylates and crosslinked polyacrylates, such as Rheocare TTA®, Cosmedia® SP, Rheocare® C Plus, Tinovis® ADE, Tinovis® GTC, are added.


Thickeners from the group of polysaccharides, such as Keltrol® T or Rheocare® XG, and thickeners such as Hydagen® 558P, Hydagen® Clean, Rheocare® XGN, Tinovis® GTC, Cosmedia® ACE are furthermore preferred.


Preferably, the amounts of thickener are in the range from 0.5 to 5 wt. %, in particular from 1 to 4 wt. %, calculated as active substance and based on total weight of the UV filter composition.


The thickeners can be added to the concentrated agent before the dilution with water is carried out or can be contained in the water with which the dilution of the concentrated agent is carried out.


According to a preferred process variant, the concentrated agent is mixed with the thickener, and water for dilution is added to this mixture and the further formulation constituents are optionally stirred in.


According to another preferred process variant, the water, the thickener and optionally the other auxiliary substances are stirred with one another and the concentrated agent is added to this mixture.


The final UV filter formulations prepared by the process according to the invention are often particularly finely divided O/W emulsion having an average particle size of <10 μm, preferably <5 μm.


Active Compounds

Biogenic active compounds which are suitable according to the invention are to be understood as meaning, for example, tocopherol, tocopherol acetate, tocopherol palmitate, ascorbic acid, (deoxy) ribonucleic acid and fragmentation products thereof,-glucans, retinol, bisabo-lol, allantoin, phytantriol, panthenol, AHA acids, amino acids, ceramides, pseudoceramides, essential oils, plant extracts, such as e.g., Prunus extract, Bambara nut extract and vitamin complexes. Such active compounds are employed in final UV filter formulations as agents which trap free radicals and serve to regenerate the skin.


Preservatives

Suitable preservatives are, for example, phenoxyethanol, formaldehyde solution, parabens, pentanediol or sorbic acid and the silver complexes known by the name Surfacine®.


Perfume Oils

Perfume oils which may be mentioned are natural, plant and animal as well as synthetic odoriferous substances or mixtures thereof. Natural odoriferous substances are obtained, inter alia, by extraction of flowers, stems, leaves, fruit, fruit peel, roots and resins of plants. Animal raw materials are furthermore possible, such as, for example, civet and castoreum. Typical synthetic odoriferous compounds are products of the ester, ether, aldehyde, ketone, alcohol and hydrocarbon type. Preferably, mixtures of various odoriferous substances which together generate a pleasant fragrance note are used.


In a preferred embodiment, the perfume is selected from limonene, citral, linalool, alpha-isomethylionon, geraniol, citronellol, 2-isobutyl-4-hydroxy-4-methyltetrahydropyrane, 2-tert.-pentylcyclohexylacetate, 3-methyl-5-phenyl-1-pentanol, 7-acetyl-1,1,3,4,4,6-hexamethylte-traline, adipine acid diester, alpha-amylcinnamaldehyde, alpha-methylionon, amyl-C-bu-tylphenylmethylpropionalcinnamal, amylsalicylate, amylcinnamylalcohol, anisealcohol, ben-zoin, benzylalcohol, benzylbenzoate, benzylcinnamate, benzylsalicylate, bergamot oil, bitter orange oil, butylphenylmethylpropiol, cardamom oil, cedrol, cinnamal, cinnamylalcohol, cit-ronnellylmethylcrotonate, lemon oil, coumarin, diethylsuccinate, ethyllinalool, eugenol, evernia furfuracea extracte, evernia prunastri extracte, farensol, guajak wood oil, hexylcinnamal, hexylsalicylate, hydroxycitronellal, lavender oil, lemon oil, linaylacetate, mandarine oil, menthyl PCA, methylheptenone, nutmeg oil, rosemary oil, sweet orange oil, terpineol, tonka bean oil, triethylcitrate, and vanillin.


Auxiliary Substances

In certain embodiments, the final UV filter formulations further comprise auxiliary substances, such as moisture-retaining agents/skin-moisturizing agents, viscosity regulators, oils, fats and waxes, surfactants, pearlescent waxes, super-oiling agents, stabilizers, cationic, zwitterionic or amphoteric polymers, further UV filters, biogenic active compounds, film-forming agents, swelling agents, hydrotropic substances, preservatives, solubilizers, perfume oils, dyestuffs, insect repellent active compounds etc., which are listed below by way of example.


Moisture-retaining agents serve to further optimize the sensory properties of the composition and for moisture regulation of the skin. The moisture-retaining agents can be present in an amount in the range of 0 to 5.0 wt. %, based on total weight of the UV filter composition.


Suitable substances are, inter alia, amino acids, pyrrolidonecarboxylic acid, lactic acid and salts thereof, lactitol, urea and urea derivative, uric acid, glucosamine, creatinine, collagen cleavage products, chitosan or chitosan salts/derivatives, and in particular polyols and polyol derivatives (e.g. glycerol, diglycerol, triglycerol, ethylene glycol, propylene glycol, butylene gly-col, erythritol, 1,2,6-hexanetriol, polyethylene glycols, such as PEG-4, PEG-6, PEG-7, PEG-8, PEG-9, PEG-10, PEG-12, PEG-14, PEG-16, PEG-18, PEG-20), sugars and sugar derivatives (inter alia fructose, glucose, maltose, maltitol, mannitol, inositol, sorbitol, sucrose, sor-bitylsilanediol, sucrose, trehalose, xylose, xylitol, glucuronic acid and salts thereof), ethoxylated sorbitol (sorbeth-6, sorbeth-20, sorbeth-30, sorbeth-40), honey and hardened honey, hardened starch hydrolysates and mixtures of hardened wheat protein and PEG-20/acetate copolymer. Substances which are preferably suitable according to the invention as moisture-retaining agents are glycerol, diglycerol, triglycerol and butylene glycol.


Possible insect repellants are, for example, N,N-diethyl-m-toluamide, 1,2-pentanediol or 3-(N-n-butyl-N-acetylamino) propionic acid ethyl ester), which is marketed by Merck KGaA under the name Insect Repellent 3535, and butylacetylaminoproprionate. They are conventionally employed in the compositions according to the invention in an amount in the range of 0 to 6 wt. %, based on total weight of the UV filter composition.


The viscosity of the agents according to the invention can be achieved by addition of viscosity regulators. Possible viscosity regulators are, inter alia, agents which impart consistency, such as e.g., fatty alcohols or hydroxy-fatty alcohols having 12 to 22 and preferably 16 to 18 carbon atoms and partial glycerides, fatty acids having 12 to 22 carbon atoms or 12-hydroxy-fatty acids. A combination of these substances with alkyl oligoglucosides and/or fatty acid N-methylglucamides of the same chain length is also suitable, since such combinations deliver particularly stable and homogeneous emulsions. The viscosity regulators also include thick-ening agents, such as, for example, Aerosil types (hydrophilic silicic acids), polysaccharides, in particular xanthan gum, guar-guar, agar-agar, alginates and tyloses, carboxymethylcellulose and hydroxyethyl- and hydroxypropylcellulose, furthermore higher molecular weight polyethylene glycol mono- and diesters of fatty acids, polyacrylates (e.g. Carbopols® and Pemu-len types from Goodrich; Synthalens& from Sigma; Keltrol types from Kelco; Sepigel types from Seppic; Salcare types from Allied Colloids), non-crosslinked and polyol-crosslinked pol-yacrylic acids, polyacrylamides, polyvinyl alcohol and polyvinylpyrrolidone. Bentonites, such as e.g., Bentone& Gel VS-5PC (Rheox), which is a mixture of cyclopentasiloxane, Disteard-imonium Hectorite and propylene carbonate, have also proved to be particularly effective. Surfactants, such as, for example, ethoxylated fatty acid glycerides, esters of fatty acids with polyols, such as, for example, pentaerythritol or trimethylolpropane, fatty alcohol ethoxylates with a narrowed homologue distribution, alkyl oligoglucosides and electrolytes, such as e.g., sodium chloride and ammonium chloride, can also be employed for regulation of the viscosity.


In the context of the invention fats and waxes are understood as meaning all lipids having a fat- or wax-like consistency which have a melting point above 20° C. These include, for example, the classic triacylglycerols, that is to say the triesters of fatty acids with glycerol, which can be of plant or animal origin. These can also be mixed esters, that is to say triesters of glycerol with various fatty acids, or a mixture of various glycerides. These also include mixtures of mono-, di- and triglycerides. So-called hardened fats and oils which are obtained by partial hydrogenation are particularly suitable according to the invention. Hardened fats and oils of plants are preferred, e.g., hydrogenated castor oil, groundnut oil, soya oil, rape oil, beet seed oil, cottonseed oil, soya oil, sunflower oil, palm oil, palm kernel oil, linseed oil, almond oil, maize oil, olive oil, sesame oil, cacao butter and coconut fat. Oxidation-stable plant glycerides which are available under the name Cegesoft® or Novata® are particularly suitable.


Possible waxes are, inter alia, natural waxes, such as e.g. candelilla wax, carnauba wax, Japan wax, esparto grass wax, cork wax, guaruma wax, rice germ oil wax, sugar cane wax, ouricury wax, montan wax, beeswax, shellac wax, spermaceti, lanolin (wool wax), uropygium fat, ceresin, ozocerite (earth wax), petrolatum, paraffin waxes, microwaxes; chemically modified waxes (hard waxes), such as e.g. montan ester waxes, Sasol waxes, hydrogenated jojoba waxes and synthetic waxes, such as e.g. polyalkylene waxes and polyethylene glycol waxes.


In addition to the fats, fat-like substances, such as lecithins and phospholipids, are also possible as additives. Lecithins are glycero-phospholipids which are formed from fatty acids, glycerol, phosphoric acid choline by esterification, and are often also called phosphatidylcholines (PC). Cephalins, which are also called phosphatidic acids and are derivatives of 1,2-diacyl-sn-glycerol-3-phosphoric acids, may be mentioned as an example of natural lecithins. In contrast, phospholipids are usually understood as meaning mono- and preferably diesters of phosphoric acid with glycerol (glycerol phosphates). Sphingosines and sphingolipids are also possible as fat-like substances.


Suitable pearlescent waxes are, for example, alkylene glycol esters, specifically ethylene gly-col distearate; fatty acid alkanolamides, specifically coconut fatty acid diethanolamide; partial glycerides, specifically stearic acid monoglyceride; esters of polybasic, optionally hydroxy-substituted carboxylic acids with C6-C22-fatty alcohols, specifically long-chain esters of tartaric acid; fatty substances, such as, for example, fatty alcohols, fatty ketones, fatty aldehydes, fatty ethers and fatty carbonates, which have at least 24 carbon atoms in total-specifically Lauron®; distearyl ether; fatty acids, such as stearic acid, C12-C22-hydroxy-fatty acids, behenic acid, ring-opening products of C12-C22-olefin epoxides with C12-C22-fatty alcohols and/or polyols having 2 to 15 carbon atoms and 2 to 10 hydroxyl groups and mixtures thereof.


Super-oiling agents which can be used are substances such as, for example, lanolin and lecithin and polyethoxylated or acylated derivatives of lanolin and lecithin, polyol fatty acid esters, monoglycerides and fatty acid alkanolamides, the latter simultaneously serving as foam stabilizers.


So-called stabilizers which can be employed are metal salts of fatty acids, such as e.g., mag-nesium, aluminum and/or zinc stearate or ricinoleate.


Suitable cationic polymers which further optimize the sensory properties of the compositions according to the invention and impart to the skin a sensation of softness are, for example, cationic cellulose derivatives, such as e.g. a quaternized hydroxyethylcellulose which is obtainable from Amerchol under the name Polymer JR 4008, cationic starch, copolymers of di-allylammonium salts and acrylamides, quaternized vinylpyrrolidone/vinylimidazole polymers, such as e.g. Luviquat® (BASF), condensation products of polyglycols and amines, quaternized collagen polypeptides, such as, for example, Lauryldimonium Hydroxypropyl Hydrolyzed Collagen (Lamequat®L/Grünau), quaternized wheat polypeptides, polyethylenimine, cationic silicone polymers, such as e.g. amodimethicone, copolymers of adipic acid and dimethylamino-hydroxypropyldiethylenetriamine (Cartaretine®/Sandoz), copolymers of acrylic acid with di-methyldiallylammonium chloride (Merquat® 550/Chemviron, polyaminopolyamides and crosslinked water-soluble polymers thereof, cationic chitin derivatives, such as, for example, quaternized chitosan, condensation products, optionally distributed in microcrystalline form, of dihaloalkyls, such as e.g. dibromobutane with bisdialkylamines, such as e.g. bis-dimethyl-amino-1,3-propane, cationic guar gum, such as e.g. Jaguar® CBS, Jaguar® C-17, Jaguar® C-16 from Celanese, quaternized ammonium salt polymers, such as e.g. Mirapol® A-15, Mirapol® AD-1, Mirapol® AZ-1 from Miranol.


Starch derivative can furthermore be employed to improve the skin sensation, e.g., Dry Flo® PC (INCI: Aluminum Starch Octenylsuccinate).


Suitable silicone compounds have already been mentioned with the oily substances. In addition to dimethylpolysiloxanes, methylphenylpolysiloxanes and cyclic silicones, amino-, fatty acid-, alcohol-, polyether-, epoxy-, fluorine-, glycoside- and/or alkyl-modified silicone compounds, which can be either liquid or resinous at room temperature, are also suitable. Sime-thicones, which are mixtures of dimethicones having an average chain length of from 200 to 300 dimethylsiloxane units and silicon dioxide or hydrogenated silicates, are furthermore suit-able.


So-called film-forming agents which lead to a further improvement in the sensory properties of the preparations according to the invention are, for example, chitosan, microcrystalline chitosan, quaternized chitosan, collagen, hyaluronic acid and salts thereof and similar compounds, and the polyvinylpyrrolidones, vinylpyrrolidone/vinyl acetate copolymers, polymers of the acrylic acid series and quaternized cellulose derivatives already mentioned under the viscosity regulators.


To improve the flow properties of the compositions according to the invention hydrotropic substances, such as, for example, ethanol, isopropyl alcohol, or polyols, can furthermore be employed. Polyols which are possible here have preferably 2 to 15 carbon atoms and at least two hydroxyl groups. The polyols can also contain further functional groups, in particular amino groups, or can be modified with nitrogen.


Dyestuffs which can be used are the substances which are suitable and approved for cosmetic purposes.


The presently claimed invention offers one or more of the following advantages:

    • 1. The present invention provides a method for increasing sun protection factor of a UV filter composition using closed-cell metal oxide particles.
    • 2. The method increases SPF of a sunscreen formulation while minimizing or masking its whitening effect and maintaining its transparency.
    • 3. The closed-cell metal oxide particles of the present invention can be used for increasing SPF of a UV filter composition.
    • 4. The closed-cell metal oxide particles of the present invention are useful for increasing SPF of a UV filter composition while minimizing or masking its whitening effect and maintaining its transparency.


In the following, there are provided a list of embodiments to further illustrate the present disclosure without intending to limit the disclosure to specific embodiments listed below.

    • 1. A method for increasing the sun protection factor of a UV filter composition, the method comprising adding closed-cell metal oxide particles to the UV filter composition,
      • wherein the closed-cell metal oxide particles comprise a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a void volume,
      • wherein the outer surface of the closed-cell metal oxide particles is defined by the array of closed-cells,
      • wherein the metal oxide matrix comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof.
    • 2. Use of closed-cell metal oxide particles for increasing the sun protection factor of a UV filter composition,
      • wherein the closed-cell metal oxide particles comprise a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a void volume,
      • wherein the outer surface of the closed-cell metal oxide particles is defined by the array of closed-cells,
      • wherein the metal oxide matrix comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof.
    • 3. The method or use according to embodiment 1 or 2, wherein the void volume is media inaccessible.
    • 4. The method or use according to any of the embodiments 1 to 3, wherein the amount of the closed-cell metal oxide particles is in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition.
    • 5. The method or use according to any of the embodiments 1 to 4, wherein the amount of the closed-cell metal oxide particles is in the range of 0.5 to 10.0 wt. % based on total weight of the UV filter composition.
    • 6. The method or use according to any of the embodiments 1 to 5, wherein the array of closed-cells is an ordered array.
    • 7. The method or use according to any of the embodiments 1 to 5, wherein the array of closed-cells is a disordered array.
    • 8. The method or use according to any of the embodiments 1 to 7, wherein the closed-cell metal oxide particles have an average diameter in the range of 0.5 μm to 100.0 μm.
    • 9. The method or use according to any of the embodiments 1 to 8, wherein the amount of metal oxide in the closed-cell metal oxide particles is in the range of 60.0 to 100.0 wt. % based on total weight of the closed-cell metal oxide particles.
    • 10. The method or use according to any of the embodiments 1 to 9, wherein the closed-cell metal oxide particles have an average pore diameter in the range of 3 nm to 500 nm.
    • 11. The method or use according to any of the embodiments 1 to 10, wherein the closed-cell metal oxide particles have an average pore diameter in the range of 3 nm to 400 nm.
    • 12. The method or use according to any of the embodiments 1 to 11, wherein the closed-cell metal oxide particles have an average pore diameter in the range of 3 nm to 300 nm.
    • 13. The method or use according to any of the embodiments 1 to 12, wherein the closed-cell metal oxide particles have an average porosity in the range of 0.10 to 0.90.
    • 14. The method or use according to any of the embodiments 1 to 13, wherein the closed-cell metal oxide particles have an average porosity in the range of 0.10 to 0.80.
    • 15. The method or use according to any of the embodiments 1 to 14, wherein the metal oxide matrix comprises silica.
    • 16. The method or use according to any of the embodiments 1 to 14, wherein the metal oxide matrix comprises silica and alumina.
    • 17. The method or use according to any of the embodiments 1 to 14, wherein the metal oxide matrix comprises silica and titania.
    • 18. The method or use according to any of the embodiments 1 to 14, wherein the metal oxide matrix comprises silica and zinc oxide.
    • 19. The method or use according to any of the embodiments 1 to 18, wherein the closed-cells are monodisperse.
    • 20. The method or use according to any of the embodiments 1 to 18, wherein the closed-cells have a bimodal distribution of monodisperse closed-cells.
    • 21. The method or use according to any of the embodiments 1 to 18, wherein the closed-cells are polydisperse.
    • 22. The method or use according to any of the embodiments 1 to 19, wherein the closed-cell metal oxide particles
      • a. have an average diameter in the range of 0.5 μm to 100.0 μm;
      • b. have an average porosity in the range of 0.10 to 0.90;
      • c. have an average pore diameter in the range of 3 nm to 500 nm; and
      • d. closed-cells are monodisperse.
    • 23. The method or use according to any of the embodiments 1 to 18 and embodiment 20, wherein the closed-cell metal oxide particles
      • a. have an average diameter in the range of 0.5 μm to 100.0 μm;
      • b. have an average porosity in the range of 0.10 to 0.90;
      • c. have an average pore diameter in the range of 3 nm to 500 nm; and
      • d. closed-cells have a bimodal distribution of monodisperse closed-cell metal oxide particles.
    • 24. The method or use according to any of the embodiments 1 to 18 and embodiment 21, wherein the closed-cell metal oxide particles
      • a. have an average diameter in the range of 0.5 μm to 100.0 μm;
      • b. have an average porosity in the range of 0.10 to 0.90;
      • c. have an average pore diameter in the range of 3 nm to 500 nm; and
      • d. closed-cells are polydisperse.
    • 25. The method or use according to any of the embodiments 1 to 24, wherein the closed-cell metal oxide particles exhibit color in the visible spectrum at a wavelength in the range of 380 nm to 800 nm.
    • 26. The method or use according to any of the embodiments 1 to 24, wherein the closed-cell metal oxide particles exhibit effect in a wavelength range in the ultraviolet spectrum in the range of 100 nm to 400 nm.
    • 27. The method or use according to any of the embodiments 1 to 26, wherein the closed-cell metal oxide particles exhibit effect in a wavelength range in the ultraviolet and visible spectrum in the range of 200 nm to 500 nm.
    • 28. The method or use according to any of the embodiments 1 to 27, wherein the UV filter composition comprises an UV absorber selected from the group consisting of
      • (d1) p-aminobenzoic acid derivatives;
      • (d2) salicylic acid derivatives;
      • (d3) benzophenone derivatives;
      • (d4) dibenzoylmethane derivatives;
      • (d5) diphenyl acrylates;
      • (d6) 3-imidazol-4-yl-acrylic acid and its esters;
      • (d7) benzofuran derivatives;
      • (d8) polymeric UV absorbers;
      • (d9) cinnamic acid derivatives;
      • (d10) camphor derivatives;
      • (d11) hydroxyphenyltriazine derivatives;
      • (d12) benzotriazole derivatives;
      • (d13) trianilino-s-triazine derivatives;
      • (d14) 2-phenylbenzimidazole-5-sulfonic acid and salts thereof;
      • (d15) methyl o-aminobenzoates;
      • (d16) homosalates;
      • (d17) tris-biphenyltriazine derivatives;
      • (d18) TiO2, ZnO and mica;
      • (d19) benzylidenemalonates;
      • (d20) merocyanine derivatives;
      • (d21) phenylene bis diphenyltriazines;
      • (d22) imidazoline derivatives;
      • (d23) diarylbutadiene derivatives;
      • (d24) amino hydroxybenzoyl hexyl benzoate derivatives;
      • (d25) bis-(diethylamino hydroxybenzoyl benzoyl)-piperazine derivatives; and mixtures thereof.
    • 29. The method or use according to any of the embodiments 1 to 28 for protecting the skin against ultraviolet radiation and high energy visible light.
    • 30. The method or use according to embodiment 29 for protecting the skin against ultraviolet radiation having a wavelength in the range from 280 and 400 nm, and high energy visible light in the range of wavelength from 380 to 480 nm.
    • 31. The method or use according to embodiment 29 or 30 for protecting the skin against high energy visible light of wavelength in the range from 380 to 480 nm.
    • 32. The method according to any of the embodiments 1 to 31, wherein the method further minimizes or masks the whitening effect of the UV filter composition and maintains its transparency.
    • 33. The use according to any of the embodiments 1 to 31, wherein the use further minimizes or masks the whitening effect of the UV filter composition and maintains its transparency.
    • 34. A UV filter composition comprising closed-cell metal oxide particles in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition,
      • wherein the closed-cell metal oxide particles comprise a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a void volume,
      • wherein the outer surface of the closed-cell metal oxide particles is defined by the array of closed-cells,
      • wherein the metal oxide matrix comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof.
    • 35. The UV filter composition according to embodiment 34, wherein the void volume is media inaccessible.
    • 36. The UV filter composition according to embodiment 34 or 35 comprising
      • a. water; and
      • b. closed-cell metal oxide particles in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition.
    • 37. The UV filter composition according to embodiment 36 comprising
      • a. water; and
      • b. closed-cell metal oxide particles in the range of 0.5 to 10.0 wt. % based on total weight of the UV filter composition.
    • 38. The UV filter composition according to embodiment 36 or 37 comprising
      • a. water;
      • b. oil; and
      • c. the closed-cell metal oxide particles in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition.
    • 39. The UV filter composition according to embodiment 38, wherein oil is present in the form of a discontinuous oil phase in the range of 5.0 to 50.0 wt. %, based on total weight of the UV filter composition.
    • 40. The UV filter composition according to embodiment 38, wherein water is present in the form of a discontinuous phase in the range of 5.0 to 50.0 wt. %, based on total weight of the UV filter composition.
    • 41. The UV filter composition according to embodiment 34 or 35 comprising
      • a. oil; and
      • b. closed-cell metal oxide particles in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition.
    • 42. The UV filter composition according to embodiment 41 comprising
      • a. oil; and
      • b. closed-cell metal oxide particles in the range of 0.5 to 10.0 wt. % based on total weight of the UV filter composition.
    • 43. The UV filter composition according to any of the embodiments 34 to 42, wherein the amount of the metal oxide in the closed-cell metal oxide particles is in the range of 60.0 to 100.0 wt. %, based on total weight of the closed-cell metal oxide particles.
    • 44. The UV filter composition according to any of the embodiments 34 to 43, wherein the closed-cell metal oxide particles have an average diameter in the range of 0.5 μm to 100.0 μm.
    • 45. The UV filter composition according to any of the embodiments 34 to 44, wherein the closed-cell metal oxide particles have an average porosity in the range of 0.10 to 0.90.
    • 46. The UV filter composition according to any of the embodiments 34 to 45, wherein the closed-cell metal oxide particles have an average porosity in the range of 0.10 to 0.80.
    • 47. The UV filter composition according to any of the embodiments 34 to 46, wherein the closed-cell metal oxide particles have an average pore diameter in the range of 3 nm to 500 nm.
    • 48. The UV filter composition according to any of the embodiments 34 to 47, wherein the UV filter composition further comprises an UV absorber selected from the group consisting of
      • (d1) p-aminobenzoic acid derivatives;
      • (d2) salicylic acid derivatives;
      • (d3) benzophenone derivatives;
      • (d4) dibenzoylmethane derivatives;
      • (d5) diphenyl acrylates;
      • (d6) 3-imidazol-4-yl-acrylic acid and its esters;
      • (d7) benzofuran derivatives;
      • (d8) polymeric UV absorbers;
      • (d9) cinnamic acid derivatives;
      • (d10) camphor derivatives;
      • (d11) hydroxyphenyltriazine derivatives;
      • (d12) benzotriazole derivatives;
      • (d13) trianilino-s-triazine derivatives;
      • (d14) 2-phenylbenzimidazole-5-sulfonic acid and salts thereof;
      • (d15). methyl o-aminobenzoates;
      • (d16) homosalates;
      • (d17) tris-biphenyltriazine derivatives;
      • (d18) TiO2, ZnO and mica;
      • (d19) benzylidenemalonates;
      • (d20) merocyanine derivatives;
      • (d21) phenylene bis diphenyltriazines;
      • (d22) imidazoline derivatives;
      • (d23) diarylbutadiene derivatives;
      • (d24) amino hydroxybenzoyl hexyl benzoate derivatives;
      • (d25) bis-(diethylamino hydroxybenzoyl benzoyl)-piperazine derivatives; and mixtures thereof.
    • 49. The UV filter composition according to any of the embodiments 34 to 48 further comprising at least one surfactant in the range of 0.1 to 20.0 wt. %, based on total weight of the UV filter composition.
    • 50. The UV filter composition according to embodiment 49, wherein the surfactant is selected from an anionic surfactant, a nonionic surfactant, and a polymeric surfactant.
    • 51. The UV filter composition according to any of the embodiments 34 to 50, further comprises additives selected from thickener, active ingredients, preservatives, and perfumes.
    • 52. The UV filter composition according to any of the embodiments 34 to 51, wherein the UV filter composition is sunscreen composition.
    • 53. The UV filter composition according to any of the embodiments 34 to 51, wherein the UV filter composition is day care composition.
    • 54. The UV filter composition according to any of the embodiments 34 to 51, wherein the UV filter composition is at least one selected from creams, gels, lotions, alcoholic solutions, aqueous/alcoholic solutions, emulsions, wax/fat compositions, stick preparations, powders and ointments.


While the presently claimed invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the presently claimed invention.


EXAMPLES

The presently claimed invention is illustrated in detail by non-restrictive working examples which follow. More particularly, the test methods specified hereinafter are part of the general disclosure of the application and are not restricted to the specific working examples.


Materials

The following materials are used in the Examples:















Eumulgin ® Prisma
is Disodium Cetearyl Sulfosuccinate;


Lanette ® O
is Cetyl stearyl Alcohol;


Cutina ® PES
is Pentaerythrityl Distearate;


Cetiol ® B
is Dibutyl Adipate;


Cetiol ® Sensoft
is Propylheptyl Caprylate;


Uvinul ® T150
is Ethylhexyl Triazone;


Tinosorb ® S
is Bis-Ethylhexyloxyphenol



Methoxyphenyl Triazine;


Uvinul ® A Plus
is Diethylamino Hydroxybenzoyl Hexyl Benzoate;


Rheocare ® XGN
is Xanthan Gum; and


Cosmedia ® SP
is Sodium Polyacrylate,



are available from BASF.









Euxyl® PE 9010 is Phenoxyethanol and Ethylhexylglycerin and is available from Ashland. Neo Heliopan® OS is Ethylhexyl Salicylate and is available from Symrise.


Methods

Average diameter or particle size: Particle size, as used herein, is synonymous with particle diameter and is determined, for example, by scanning electron microscopy (SEM) or transmission electron microscopy (TEM). Average particle size is synonymous with D50, meaning half of the population resides above this point, and the other half resides below this point. Particle size refers to primary particles. Particle size may be measured by laser light scattering techniques with dispersions or dry powders.


Average porosity and average pore diameter: Mercury porosimetry analysis can be used to characterize the porosity of the particles. Mercury porosimetry applies controlled pressure to a sample immersed in mercury. External pressure is applied for the mercury to penetrate into the voids/pores of the material. The amount of pressure required to intrude into the voids/pores is inversely proportional to the size of the voids/pores. A mercury porosimeter generates volume and pore size distributions from the pressure versus intrusion data generated by the instrument using the Washburn equation. Porosity, as reported herein for closed-cell metal oxide particles, is calculated as a ratio of unoccupied space and total particle volume. For example, porous silica particles containing voids/pores with an average size of 165 nm have an average porosity of 0.8.


Determination of the in vitro SPF of Formulation examples The determination of the in vitro SPF is performed by measuring the diffuse transmission in the UV-range using a Labsphere Ultraviolet Transmittance Analyzer 2000S. In order to simu-late the inhomogeneous surface structure of human skin, substrates with rough or porous surface are taken for such measurements. For this method Sandblasted 4-5 μm PMMA (PolyMethylMethacrylate) plates, from Helioscience (France), are used as substrate.


The sunburn protection factor (SPF) formalism was first introduced by Sayre in 1979 [1], by which an average of the inverse transmission (1/T) of the respective sunscreen in the spectral range between 290 and 400 nm is calculated, including weighting with the irradiance spectrum of a UV source, Ss (2), and the erythemal action spectrum, Ser (2):






?







?

indicates text missing or illegible when filed




REFERENCES



  • [1] R. M. Sayre, P. P. Agin, G. J. LeVee, E. Marlowe. A comparison of in vivo and in vitro testing of sunscreening formulas, Photochem. Photobiol. 29 (1979) 559-566



Transparency/whitening method: Color measurements were performed with the prepared compositions applied on PMMA plates also used for in vitro SPF measurement. From the obtained L*a*b* parameters L* refers to the lightness of a sample. The difference of L* to a blank sample is expressed as delta L* and can be used to compare the transparency or whitening of the samples.


Experiments

Preparation of closed-cell metal oxide particles


Example 1: Preparation of Closed-Cell Silica Particles

An aqueous dispersion of positively charged poly(meth)acrylate nanoparticle was diluted to 1 wt. % with deionized water and 3 wt. % of negatively charged silica nanoparticles was added. The mixture was sonicated for 30 seconds to prevent agglomeration. The aqueous nanoparticle dispersion and oil phase (a continuous oil phase containing 2 wt. % of polyethylene gly-col-co-perfluoro polyester surfactant in fluorinated oil) were each injected into a microfluidic device having a 50 μm droplet junction via syringe pumps. The system was allowed to equilibrate until monodispersed droplets were produced. The droplets were collected in a reservoir.


Collected droplets were dried in an oven at 50° C. for 4 hours. The dried powder was calcined by placing on a silicon wafer, heating from room temperature to 500° C. over a 4 hour period, holding at 500° C. for 2 hours, and cooling back to room temperature over a 4 hour period. The procedure resulted in monodispersed closed-cell silica particles having a diameter of 15 micrometers.


Example 2: Preparation of Closed-Cell Silica Particles with Ordered Voids

An aqueous suspension of positively charged spherical polymer nanoparticles (copolymer of methyl methacrylate and 2-(methacryloyloxy) ethyl] trimethylammonium chloride nanoparticles having an average diameter of 436 nm) and negatively charged silica nanoparticles (having an average diameter of 7 nm) was prepared. The polymer nanoparticles were present at 1.8 wt. % and the silica nanoparticles were present at 0.6 wt. % based on a weight of the aqueous suspension (a 3:1 weight to weight ratio of polymer nanoparticles to metal oxide nanoparticles). The aqueous suspension was spray dried under an inert atmosphere (nitrogen) at a 100° C. inlet temperature, a 40 mm spray gas pressure, a 100% aspirator rate, and a 30% flow rate (about 10 mL/min) using a BÜCHI lab-scale spray dryer.


The spray dried powder was removed from the spray dryer's collection chamber and spread onto a silicon wafer for sintering. The spray dried powder was then calcined in a muffle furnace with a batch sintering process to sinter and densify the silica nanoparticles and remove the polymer to produce the closed-cell silica particles. The heating parameters were as follows: the particles were heated from room temperature to 550° C. over a period of 5 hours, held at 550° C. for 2 hours, and then cooled back to room temperature over a period of 3 hours. The average closed-cell silica particles diameter was 3.2+1.4 μm.


The SEM images of a closed-cell silica particle produced as well as a cross-section of a closed-cell silica particle showed that the interior structure comprise an array of closed-cell silica shells that each encompass relatively monodisperse and ordered voids.


Example 3: Preparation of Closed-Cell Titania Particles

An aqueous suspension of negatively charged spherical polystyrene nanoparticles (having an average diameter of 197 nm) and positively charged titania nanoparticles (having an average diameter of 15 nm) was prepared. The polymer nanoparticles were present at 1.8 wt. % and the titania nanoparticles were present at 1.2 wt. % based on a weight of the aqueous suspension (a 3:2 weight to weight ratio of polymer nanoparticles to metal oxide nanoparticles). The aqueous suspension was spray dried under an inert atmosphere (nitrogen) at a 100° C. inlet temperature, a 55 mm spray gas pressure, a 100% aspirator rate, and a 30% flow rate (about 10 mL/min) using a BÜCHI lab-scale spray dryer.


The spray dried powder was removed from the spray dryer's collection chamber and spread onto a silicon wafer for sintering. The spray dried powder was then calcined in a muffle furnace with a batch sintering process to sinter and densify the titania nanoparticles and remove the polymer to produce the closed-cell titania particles. The heating parameters were as follows: the particles were heated from room temperature to 300° C. over a period of 4 hours, held at 300° C. for 6 hours, and then heated to 550° C. over a period of 2 hours, held at 550° C. for 2 hours, and cooled back to room temperature over a period of 4 hours. The average closed-cell titania particles diameter was 2.8+1.5 μm.


The SEM images of a closed-cell titania particle produced as well as a cross-section of a closed-cell titania particle showed that the interior structure comprises an array of closed-cell titania shells that each encompass relatively monodisperse voids.


Example 4: Preparation of closed-cell silica particle via sol-gel process

An aqueous suspension of positively charged spherical polymer nanoparticles (copolymer of methyl methacrylate and 2-(methacryloyloxy) ethyl trimethylammonium chloride nanoparticles having an average diameter of 254 nm) and silica precursor tetramethyl orthosilicate (TMOS) was mixed in the pH range of 2-5. The polymer nanoparticles were present at 1.8 wt. % and the TMOS were present at 3.6 wt. % based on a weight of the aqueous suspension (a 1:3 weight to weight ratio of polymer nanoparticles to metal oxide). The aqueous suspension was spray dried under an inert atmosphere (nitrogen) at a 100° C. inlet temperature, a 40 mm spray gas pressure, a 100% aspirator rate, and a 30% flow rate (about 10 mL/min) using a BÜCHI lab-scale spray dryer.


The spray dried powder was removed from the spray dryer's collection chamber and spread onto a silicon wafer for sintering. The spray dried powder was then calcined in a muffle furnace with a batch sintering process to convert silica precursor to silica nanoparticles and densify the silica, and remove the polymer to produce closed-cell silica particles. The heating parameters were as follows: the particles were heated from room temperature to 200° C. over a period of 3 hours, held at 200° C. for 2 hours, and then heated to 550° C. over a period of 2 hours, held at 550° C. for 2 hours and cooled back to room temperature over a period of 3 hours. The average closed-cell silica particle diameter was 3.0+1.7 μm.


Example 5: Preparation of Closed-Cell Silica Particles with Disordered Voids

An aqueous suspension of two different sized (254 nm and 142 nm in diameter, respectively) positively charged spherical polymer nanoparticles (co-polymer of methyl methacrylate and 2-(methacryloyloxy) ethyl trimethylammonium chloride nanoparticles) and negatively charged silica nanoparticles (having an average diameter of 7 nm) was prepared. The polymer nanoparticles were present at 1.8 wt. % in total (0.9 wt. % of each) and the silica nanoparticles were present at 0.6 wt. % based on a weight of the aqueous suspension. The aqueous suspension was spray dried under an inert atmosphere (nitrogen) at a 100° C. inlet temperature, a 40 mm spray gas pressure, a 100% aspirator rate, and a 30% flow rate (about 10 mL/min) using a BÜCHI lab-scale spray dryer.


The spray dried powder was removed from the spray dryer's collection chamber and spread onto a silicon wafer for sintering. The spray dried powder was then calcined in a muffle furnace with a batch sintering process to convert silica precursor to silica nanoparticles and densify the silica, and remove the polymer to produce closed-cell silica particles. The heating parameters were as follows: the particles were heated from room temperature to 550° C. over a period of 6 hours, held at 550° C. for 2 hours, and then cooled back to room temperature over a period of 4 hours. The average closed-cell silica particle diameter was 2.1+1.2 μm.


The closed-cell silica particles (0.5 mg) were evenly distributed in a 20-mL clear glass vial having a 6 cm2 bottom surface. The sample exhibited an angle-independent blue color that was observable by the human eye.


Determination of Properties

Experiment 1: Sun protection factor (SPF) experiments


The UV-filter compositions according to Table 1 were prepared for the evaluation of SPF of the closed cell metal oxide particles.


Composition 1 was basic (placebo) composition which contained the following UV filters: Ethylhexyl Triazone, bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, Diethylamino Hydroxybenzoyl Hexyl Benzoate and Ethylhexyl Salicylate. Suitable additives were also present in the composition.


Composition 2 was the composition of the presently claimed invention having 3.00 wt. % of closed-cell metal oxide particles prepared according to Example 2.


Composition 3 is a composition for comparative analysis having 3.00 wt. % of commercial SunSpheres™ polymer boosts for UV protection instead of the closed cell metal oxide particles.


Composition 4 was a composition for comparative analysis having 3.00 wt. % of commercial porous silica microspheres instead of the closed cell metal oxide particles.



















Composition 1
Composition 2
Composition 3
Composition 4




Placebo-
Closed-cell
for
for




without
metal oxide
comparative
comparative


Trade name
INCI
particles
particles
analysis
analysis




















Eumulgin ®
Disodium Cetearyl
1.00
1.00
1.00
1.00


Prisma
Sulfosuccinate


Lanette ® O
Cetearyl Alcohol
2.00
2.00
2.00
2.00


Cutina ® PES
Pentaerythrityl
2.00
2.00
2.00
2.00



Distearate


Cetiol ® B
Dibutyl Adipate
10.00
10.00
10.00
10.00


Cetiol ® Sensoft
Propylheptyl Caprylate
5.00
5.00
5.00
5.00


Euxyl ® PE 9010
Phenoxyethanol and
1.00
1.00
1.00
1.00



Ethylhexylglycerin


Uvinul ® T150
Ethylhexyl Triazone
3.00
3.00
3.00
3.00


Tinosorb ® S
Bis-Ethylhexyloxyphenol
3.00
3.00
3.00
3.00



Methoxyphenyl Triazine


Uvinul ® A Plus
Diethylamino
7.00
7.00
7.00
7.00



Hydroxybenzoyl Hexyl



Benzoate


Neo Heliopan ® OS
Ethylhexyl Salicylate
5.00
5.00
5.00
5.00


Water
Aqua
57.30
54.30
54.30
54.30


Glycerine
Glycerine
3.00
3.00
3.00
3.00


Rheocare ® XGN
Xanthan Gum
0.20
0.20
0.20
0.20


Cosmedia ® SP
Sodium Polyacrylate
0.50
0.50
0.50
0.50


Particle
Closed-cell

3.00





microsphere according



to example 2


Particle
Sunspheres ™


3.00



Particle
Sunsil-130



3.00









The SPF values of these compositions was measured according to in vitro SPF method ISO24444 and the results are summarized in Table 2.









TABLE 2







In vitro SPF evaluation of UV filter compositions














Composition 3
Composition 4





for
for



Composition 1

comparative
comparative


Composition
Placebo
Composition 2
analysis
analysis





Added particles
No particles
3 wt. % Closed-
3 wt. %
3 wt. %




cell metal oxide
Sunspheres ™
Sunsil-130




particles




according to




example 2


in vitro SPF
32.2
44.3
43.8
31.2


(ISO 24444)










FIG. 1 shows the absorbance of the UV filter compositions 1, 2 and 4 in the range from 290 to 450 nm.


The composition 2 with 3 wt. % of closed cell metal oxide particles of Example 2 showed increased absorption over the whole UV range from 290 to 450 nm. The in vitro SPF of the composition could be increased by 27% with addition of 3 wt. % of closed-cell metal oxide particles according to example 2 as compared to the Placebo Composition 1. In contrast the in vitro SPF of composition 4 containing 3% porous metal oxide particles (silica, Sunsil-130) remained about the same as for the Placebo Composition 1.



FIG. 2 shows the absorbance of the UV filter compositions 1, 2 and 3 in the range from 290 to 450 nm. The composition 2 with 3 wt. % of closed-cell metal oxide particles of Example 2 was compared with reference composition 3 comprising 3% commercial polymeric UV protection boosts SunSpheres™ instead of the closed-cell metal oxide particles. The results are shown in FIG. 2.


It was evident from FIG. 2 that the closed cell metal oxide particles showed results comparable to the commercial polymer boost.


Experiment 2: Transparency/Whitening Experiments

The whitening effect was determined for the compositions 1, 2, and 3 prepared in experiment 2 by color measurement as described above. The results for formulations with UV-filters are summarized in FIG. 3.


It was observed from FIG. 3 that composition 3 (containing 3% Sunspheres®) scatters the visible light significantly and thus produces strong whitening effect on the skin. FIG. 3 shows that delta L* of Composition 3 increases to 12 (4.5 units or 57 percentage points compared to Placebo Composition 1) whereas delta L* of composition 2 (3% closed-cell particles) only increases to 8.5 (1.0 unit or 11 percentage points compared to Placebo Composition 1). The closed-cell metal oxide particles of the present invention do not produce a visible whitening effect, because only differences of delta L* greater than 4 can be recognized by the untrained human eye.

Claims
  • 1-28. (canceled)
  • 29. A method for increasing the sun protection factor of a UV filter composition, the method comprising adding closed-cell metal oxide particles to the UV filter composition, wherein the closed-cell metal oxide particles comprise a metal oxide matrix defining an array of closed-cells, each closed-cell encapsulating a void volume,wherein the outer surface of the closed-cell metal oxide particles is defined by the array of closed-cells,wherein the metal oxide matrix comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof.
  • 30. The method according to claim 29, wherein the void volume is media inaccessible.
  • 31. The method according to claim 29, wherein the amount of the closed-cell metal oxide particles is in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition.
  • 32. The method according to claim 29, wherein the array of closed-cells is an ordered array.
  • 33. The method according to claim 29, wherein the array of closed-cells is a disordered array.
  • 34. The method according to claim 29, wherein the closed-cell metal oxide particles have an average diameter in the range of 0.5 μm to 100.0 μm.
  • 35. The method according to claim 29, wherein the amount of metal oxide in the closed-cell metal oxide particles is in the range of 60.0 to 100.0 wt. % based on total weight of the closed-cell metal oxide particles.
  • 36. The method according to claim 29, wherein the closed-cell metal oxide particles have an average pore diameter in the range of 3 nm to 500 nm.
  • 37. The method according to claim 29, wherein the closed-cell metal oxide particles have an average porosity in the range of 0.10 to 0.90.
  • 38. The method according to claim 29, wherein the metal oxide matrix comprises silica.
  • 39. The method according to claim 29, wherein the closed-cell metal oxide particles a. have an average diameter in the range of 0.5 μm to 100.0 μm;b. have an average porosity in the range of 0.10 to 0.90;c. have an average pore diameter in the range of 3 nm to 500 nm; andd. closed-cells are monodisperse.
  • 40. The method according to claim 29, wherein the closed-cell metal oxide particles a. have an average diameter in the range of 0.5 μm to 100.0 μm;b. have an average porosity in the range of 0.10 to 0.90;c have an average pore diameter in the range of 3 nm to 500 nm; andd. closed-cells have a bimodal distribution of monodisperse closed-cell metal oxide particles.
  • 41. The method according to claim 29, wherein the closed-cell metal oxide particles a. have an average diameter in the range of 0.5 μm to 100.0 μm;b. have an average porosity in the range of 0.10 to 0.90;c. have an average pore diameter in the range of 3 nm to 500 nm; andd. closed-cells are polydisperse.
  • 42. The method according to claim 29, wherein the closed-cell metal oxide particles exhibit color in the visible spectrum at a wavelength in the range of 380 nm to 800 nm.
  • 43. The method according to claim 29, wherein the UV filter composition comprises at least one UV absorber selected from the group consisting of (d1) p-aminobenzoic acid derivatives;(d2) salicylic acid derivatives;(d3) benzophenone derivatives;(d4) dibenzoylmethane derivatives;(d5) diphenyl acrylates;(d6) 3-imidazol-4-yl-acrylic acid and its esters;(d7) benzofuran derivatives;(d8) polymeric UV absorbers;(d9) cinnamic acid derivatives;(d10) camphor derivatives;(d11) hydroxyphenyltriazine derivatives;(d12) benzotriazole derivatives;(d13) trianilino-s-triazine derivatives;(d14) 2-phenylbenzimidazole-5-sulfonic acid and salts thereof;(d15) methyl o-aminobenzoates;(d16) homosalates;(d17) tris-biphenyltriazine derivatives;(d18) TiO2, ZnO and mica;(d19) benzylidenemalonates;(d20) merocyanine derivatives;(d21) phenylene bis diphenyltriazines;(d22) imidazoline derivatives;(d23) diarylbutadiene derivatives;(d24) amino hydroxybenzoyl hexyl benzoate derivatives;(d25) bis-(diethylamino hydroxybenzoyl benzoyl)-piperazine derivatives; andmixtures thereof.
  • 44. The method according to claim 29 for protecting the skin against ultraviolet radiation and high energy visible light.
  • 45. The method according to claim 29, wherein the method further minimizes or masks the whitening effect of the UV filter composition and maintains its transparency.
  • 46. A UV filter composition comprising closed-cell metal oxide particles in the range of 0.1 to 25.0 wt. % based on total weight of the UV filter composition, wherein the closed-cell metal oxide particles comprise a metal oxide matrix defining an array of closed-cells, each closed cell encapsulating a void volume,wherein the outer surface of the closed-cell metal oxide particles is defined by the array of closed-cells,wherein the metal oxide matrix comprises at least one metal oxide selected from the group consisting of silica, titania, alumina, zirconia, ceria, iron oxides, zinc oxide, indium oxide, tin oxide, chromium oxide, and mixtures thereof.
  • 47. The UV filter composition according to claim 46, wherein the void volume is media inaccessible.
  • 48. The UV filter composition according to claim 46, wherein the UV filter composition further comprises at least one UV absorber selected from the group consisting of (d1) p-aminobenzoic acid derivatives;(d2) salicylic acid derivatives;(d3) benzophenone derivatives;(d4) dibenzoylmethane derivatives;(d5) diphenyl acrylates;(d6) 3-imidazol-4-yl-acrylic acid and its esters;(d7) benzofuran derivatives;(d8) polymeric UV absorbers;(d9) cinnamic acid derivatives;(d10) camphor derivatives;(d11) hydroxyphenyltriazine derivatives;(d12) benzotriazole derivatives;(d13) trianilino-s-triazine derivatives;(d14) 2-phenylbenzimidazole-5-sulfonic acid and salts thereof;(d15) methyl o-aminobenzoates;(d16) homosalates;(d17) tris-biphenyltriazine derivatives;(d18) TiO2, ZnO and mica;(d19) benzylidenemalonates;(d20) merocyanine derivatives;(d21) phenylene bis diphenyltriazines;(d22) imidazoline derivatives;(d23) diarylbutadiene derivatives;(d24) amino hydroxybenzoyl hexyl benzoate derivatives;(d25) bis-(diethylamino hydroxybenzoyl benzoyl)-piperazine derivatives, andmixtures thereof.
  • 49. The UV filter composition according to claim 46 further comprising at least one surfactant in the range of 0.1 to 20.0 wt. %, based on total weight of the UV filter composition.
  • 50. The UV filter composition according to claim 49, wherein the surfactant is selected from an anionic surfactant, a nonionic surfactant, and a polymeric surfactant.
  • 51. The UV filter composition according to claim 46 further comprises additives selected from thickener, active ingredients, preservatives, and perfumes.
  • 52. The UV filter composition according to claim 46, wherein the UV filter composition is a sunscreen composition.
  • 53. The UV filter composition according to claim 46, wherein the UV filter composition is a day care composition.
  • 54. The UV filter composition according to claim 46, wherein the UV filter composition is at least one selected from creams, gels, lotions, alcoholic solutions, aqueous/alcoholic solutions, emulsions, wax/fat compositions, stick preparations, powders and ointments.
Priority Claims (1)
Number Date Country Kind
22151984.6 Jan 2022 EP regional
PCT Information
Filing Document Filing Date Country Kind
PCT/EP2023/050922 1/17/2023 WO